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ABSTRACT 
David S. Paul 
THE EFFECTS OF ARSENIC ON GLUCOSE METABOLISM IN 
IN VIVO AND IN VITRO MODELS 
(Under the direction of Miroslav Stýblo) 
 
 Epidemiologic studies have reported an increased prevalence of type 2 diabetes 
mellitus in populations exposed to high levels of inorganic arsenic (iAs) in drinking-water.  
Laboratory research suggests that arsenicals may interfere with processes related to glucose 
metabolism.  This dissertation describes research that: 1) Examines the mechanisms 
responsible for the inhibition of insulin-stimulated glucose uptake (ISGU) in cultured 
adipocytes and 2) Establishes an in vivo model for arsenic-induced diabetes using C57BL/6 
mice. 
 We examined the effects of arsenite (iAsIII) and its trivalent metabolites, 
methylarsonous acid (MAsIII), and dimethylarsinous acid (DMAsIII) on components of the 
insulin-activated signal transduction pathway that regulate ISGU in murine 3T3-L1 
adipocytes.  We demonstrated that subtoxic concentrations of iAsIII and MAsIII inhibit ISGU 
in adipocytes through a mechanism that involves the inhibition of phosphoinositide 
dependent kinase-1 (PDK-1) catalyzed phosphorylation of protein kinase B (PKB/Akt).  The 
mechanisms responsible for the inhibition of ISGU by DMAsIII were found to be independent 
of PKB/Akt activation. 
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 Male C57BL/6 mice were used to establish an in vivo model for arsenic-induced 
diabetes.  Mice were exposed to 25 and 50 ppm of iAsIII in drinking-water for 8 weeks.  
Subsequent intraperitoneal glucose tolerance tests demonstrated that glucose tolerance was 
impaired in mice exposed to 50 ppm arsenic, but not 25 ppm arsenic.  Exposures to 25 and 50 
ppm arsenic in drinking-water resulted in proportional increases in the concentration of iAs 
and its metabolites in tissues responsible for glucose metabolism and homeostasis, including 
the liver, pancreas, skeletal muscle and adipose tissue.  Notably, the average concentration of 
total speciated arsenic in livers of mice in the 50 ppm group was comparable to the highest 
concentration of total arsenic reported in livers of Bangladeshi residents who had consumed 
water with an order of magnitude lower concentration of iAs.  These data suggest that mice 
are less susceptible than humans to the diabetogenic effects of chronic exposures to iAs in 
drinking-water, possibly due to the more efficient clearance of arsenic from target tissues.   
 This dissertation demonstrates the capacity of iAs and its metabolites to disrupt 
insulin signaling and insulin-dependent glucose metabolism in a manner that is consistent 
with diabetes mellitus. 
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INTRODUCTION  
 
1.1 Arsenic and Diabetes 
 Type 2 diabetes mellitus accounts for 90-95% of all diabetes cases worldwide.  It is 
characterized by severe glucose intolerance resulting from inadequate responses to insulin 
stimulus by glucose metabolizing tissues, such as the liver, skeletal muscle and adipose 
tissue.  The resistance of these tissues to insulin may ultimately result in a deficiency of 
insulin production by the pancreas. A variety of genetic and lifestyle factors are known to 
contribute to the development of the type 2 diabetes.  Obesity is considered the single most 
important risk factor for this disease, however, some studies have suggested that exposures 
to environmental contaminants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin, N-nitroso 
compounds or various arsenic-species may be associated with an increased risk of diabetes 
(3).  Data regarding the association between environmental contaminants and diabetes are 
most convincing for exposures to inorganic arsenic (iAs).  For example, in Taiwan, an 
increased prevalence of diabetes has been reported in populations that ingest drinking-water 
containing high levels of iAs.  Similar findings have been reported by epidemiologic studies 
of populations in arsenic-endemic areas in India, Bangladesh and Mexico that are 
chronically exposed to iAs in drinking-water.  Studies examining occupational arsenic 
exposures in Denmark, Sweden, and Finland have also suggested an association between 
arsenic and risk of diabetes. 
 This project was designed to investigate the capacity of iAs and its methylated 
metabolites to interfere with glucose homeostasis and provide a mechanistic basis for the 
development of arsenic-induced diabetes in populations that are chronically exposed to iAs 
in drinking-water. 
1.2 Sources of Environmental Arsenic 
 Arsenic is a toxic metalloid that is widely distributed throughout the earth’s crust in 
several allotropic forms and is a major constituent of more than 200 mineral species.  
Geologists have estimated that arsenic is the 20th most abundant element in the earth’s crust 
with an average concentration of 2 mg/kg (4).  Arsenopyrite, a mineral complex of arsenic, 
sulfur and iron, is the most commonly occurring form of arsenic found in the environment.  
Environmental arsenic is present in a wide variety of chemical species and may be subjected 
to various types of transformations including redox reactions, ionic substitutions, and 
biotransformation as a result of biological processes.  These reactions result in the production 
of inorganic and organic arsenic species of varying chemical complexity and distribution in 
the environment.  The chemical form of arsenic is the principal factor in determining the 
degree and character of its biological effects. 
 Volcanic activity and low temperature volatilization, the conversion of solids or 
liquids to gas, are the greatest natural suppliers of arsenic to the environment. Other natural 
contributors to environmental arsenic-load are related to its weathering or leaching from 
minerals and geological strata that are subjected to the forces of wind and water.  The 
smelting of non-ferrous metals, and the production of energy from coal burning, are the two 
most significant anthropogenic sources of arsenic.  Other sources of environmental arsenic 
contamination include the manufacture and use of agricultural pesticides, herbicides, and 
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livestock feed-additives containing iAs or organic arsenic species.  The widespread use of 
pesticides containing chromated copper arsenate (CCA) in lumber production may also 
represent a significant source of localized contamination (5). 
1.3 Human Exposure to Arsenic 
 Arsenic from natural and anthropogenic sources is widely distributed in the 
environment and can be found in virtually every sample of soil, air or water.  In general, 
human exposure to arsenic from contaminated soil or air is insignificant and not a major 
contributor to negative health effects associated with arsenic exposure.  In contrast, 
ingestion of iAs-contaminated drinking-water represents a major source of human exposure 
and has been shown to contribute to numerous negative health effects in chronically exposed 
populations throughout the world (Fig. 1.1).  The contamination of groundwater with iAs 
reportedly exceeds the U.S. Environmental Protection Agency’s (EPA) maximum 
contaminant level (MCL) of 10 μg/L in numerous countries, including Argentina, Australia, 
Bangladesh, Chile, China, Hungary, India, Mexico, Peru, Taiwan, and the United States of 
America (6).  Table 1.1 provides a brief summary of the data regarding arsenic-containing 
groundwater in these countries where serious negative health effects are associated with 
chronic ingestion of drinking-water containing iAs have been documented.  Perhaps the 
greatest and most profound contamination of groundwater has been reported in Bangladesh 
and West Bengal, India (7).  Approximately 34,000 tube wells exist throughout Bangladesh, 
of which 56% contain arsenic levels >10 μg/L and 37% contain >50 μg/L (Fig. 1.2) (8).  It 
is estimated that 28 – 35 million people Bangladesh consume groundwater containing >50 
μg/L (6).     
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Table 1.1:  Selected data of reported arsenic contamination of                                         
groundwater in countries around the world (2,6,9-11) 
Country Affected Region Range of arsenic 
concentrations 
Population Exposed 
Argentina Chaco-Pampean Plains 100 – 2,000 mg/L in some locations 200,000 
Bangladesh Ganges Delta <.25 μg/L – 1,600 μg/L 46-57 million exposed to >10 μg/L 
Chile Arica Province, Northern Chile not available 400,000 
China Inner Mongolia: Shaanxi and Xinjiang Provinces 
90% of wells tested contain 
>50 μg/L, highest detected 
= 2,400 μg/L 
1.7 million 
Hungary Great Hungarian Plain 2 – 176 μg/L 400,000 
India West Bengal not available 5 million 
Mexico Lagunera and Zimapan Regions 
1 – 500 μg/L              
(mean of 100 μg/L) 400,000 
Taiwan Villages in Southeastern Region 50 μg/L – 640 μg/L 240,000 
USA California, Nevada, South Dakota, Alaska 10 μg/L – 50 μg/L 
13 million exposed to 
>10 μg/L 
Figure 1.1: Arsenic contamination of groundwater supplies in countries around the world (2)
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According to the U.S. EPA, 13 million people in the U.S. may be exposed to arsenic in 
drinking-water at levels exceeding the 10 μg/L, with concentrations exceeding 50 μg/L is 
some locations (Fig. 1.3).  Recent studies have reported that residents of some Taiwanese 
villages ingest drinking-water containing 50 – 640 μg of iAs/L of water.  Assuming an 
average consumption of 2 L of water per day, individuals living in arsenic-endemic villages 
may consume 100 – 1,280 μg of iAs/day.  Even higher daily intakes of iAs are expected in 
Bangladesh, where iAs levels in water may exceed 1,600 μg/L (Table 1.1). 
Figure 1.2:  Contamination of groundwater with arsenic in Bangladesh.  Left panel--
Concentration of arsenic in tube wells.  Right panel—Estimates of population per km2 that are 
exposed to arsenic in drinking-water exceeding 50 μg/L (2). 
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Figure 1.3:  Concentrations of arsenic in groundwater supplies in the U.S. (1) 
 
 The presence of arsenic in virtually all foods and beverages consumed by humans is a 
consequence of its ubiquitous distribution in the environment.  Therefore, dietary intake 
may represent an additional source of arsenic exposure, independent of occupational 
exposure or consumption of arsenic-containing drinking-water. In general, marine fish, 
shellfish, and seaweed are the largest contributors of dietary arsenic intake, owing to the 
relatively high concentrations of arsenic found in these organisms, predominantly in the 
form of non-toxic arsenobetaine.  Thus, populations in which seafood is a major component 
of the diet are likely to be exposed to greater amounts arsenic than populations consuming 
primarily terrestrial diets.  Notable exceptions to this generality include populations living in 
West Bengal, and Bangladesh who receive the majority of their dietary arsenic from locally 
grown rice and vegetables (12-14) irrigated with arsenic-containing groundwater.  
Numerous studies have been conducted to estimate dietary arsenic intake in different 
populations.  As illustrated in Table 1.2, these data provide some indication of the variation 
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in dietary arsenic intake between countries.  These studies report only total-arsenic levels 
(tAs) with no indication of the arsenic species, therefore conclusions regarding the risks of 
arsenic-induced health problems are impossible.  It should be stressed that for most 
populations, the amount of arsenic ingested from dietary sources is relatively small and 
often in the form of less biologically reactive arsenic compounds that have not been 
associated with arsenic-related diseases.  Populations living in arsenic-endemic areas may 
consume up to one-thousand times more arsenic in drinking-water than would be expected 
from the diet. 
Table 1.2:  Estimated average dietary intake of arsenic in selected countries 
Country 
(reference) 
Subjects 
Dietary arsenic 
intake 
(μg/day) 
Adult males 73 
Adult females 53 Australia (15) 
Children (2 years) 17 
Students 19 
S. Catarina 1 region 53 Brazil (16) 
Manaus region 140-159 
Adult males 59 
Canada (17) 
Children (1-4 years) 15 
Japan (18) Adults 182 
Spain (19)  Adults 291 
Britain (20) Adults 63 
Adult males (25-30 years) 57 
Adult females (25-30 years) 28 USA (21) 
Children (2 years) 23 
Adults 189 West Bengal 
(12) Children 102 
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1.4 Arsenic Metabolism 
 Human exposure to arsenic is inevitable. As previously mentioned the toxicity of 
ingested arsenicals is highly variable and depends, not only on the species of arsenic 
ingested, but also on important factors such as, their bioavailability and metabolic 
transformation once ingested.  This section will discuss factors related to the metabolism of 
arsenic and the relevance of these factors with respect to the effects of arsenic on human 
health. 
 
1.4.1 Bioavailability of Arsenic 
 Bioavailability is a measure of the physicochemical access that a toxicant has to the 
biological processes of an organism. In general, the less the bioavailability of a toxicant, the 
less its toxic effect on an organism.  The bioavailability of arsenic is greatly dependent on the 
species of arsenic as well as the route of exposure.  Arsenic can gain access into the body via 
absorption through the skin or respiratory tract; however the predominant route of exposure 
is via the gastrointestinal tract.  
 Dermal exposure to arsenic may occur via direct contact with arsenic-containing 
water or soil, as well as CCA treated wood or agricultural products.  The absorption of 
arsenic by skin is poor and primarily dependent on the solubility of the arsenic-species and 
the characteristics of the containing medium.  Several in vivo and in vitro studies have been 
conducted to quantify the absorption of different arsenicals by the skin as well as determine 
how different vehicles may affect absorption.  In general, water soluble arsenicals are 
absorbed by the skin to a greater degree than insoluble arsenic-species.  Dermal absorption of 
arsenate (iAsV) has been examined because it is one of the most water soluble forms of 
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arsenic and is therefore abundant in the groundwater of certain locales.  The absorption of 
iAsV by isolated dorsal skin from B6C3F1 mice was shown to be independent of 
concentration but highly dependent on vehicle volume (22).  Dermal absorption of iAsV from 
soil is typically very low, with less than 0.3% of administered arsenic being absorbed by 
isolated skin sections.  Although these results suggest that dermal absorption of arsenic is 
limited, it may represent an additional contributor to arsenic-load in individuals that depend 
on arsenic-contaminated water for daily living activities. 
 Inhalation of arsenic-containing particles may be a consequence of occupational 
exposures to metal smelting, coal-burning, glass blowing or cigarette smoking.  The uptake 
of arsenic by the respiratory tract involves the deposition of arsenic-containing particulate 
matter on the epithelial surfaces of the trachea and lungs followed by the absorption of 
arsenic from the deposited particles.  The absorption of arsenic species from particulate 
matter by respiratory epithelia is directly correlated with their solubility.  For example, 
approximately 99.94% of highly soluble sodium arsenite (2 mg/kg) was absorbed by the 
lungs of exposed hamsters compared to 55.5% of the relatively insoluble lead arsenate (23).  
The most common route of arsenic inhalation is via cigarette smoking which is estimated to 
account for 10 μg of arsenic intake for a person in U.S. smoking 40 cigarettes per day (24).   
 Gastrointestinal absorption of arsenic, resulting from the ingestion of arsenic-
containing food, water, beverages or medicines, depends primarily on the solubility of the 
ingested arsenical.  The bioavailability of intestinally ingested arsenic also depends on the 
matrix in which it is ingested as well as the presence of nutrients or bacterial microflora in 
the GI tract.  It has been demonstrated that diets low in fiber result in a 10% increase in 
intestinal absorption of iAsV by female B6C3F1 mice (25).  Unabsorbed arsenicals are 
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typically excreted in the feces.  The highly efficient absorption of arsenicals by the GI tract 
underscores the importance of limiting the amount of arsenic present in food, beverages and 
water supplies and minimizing the intake of items that contain high levels of arsenic.  
 
1.4.2 Arsenic Transport 
 Research of arsenic transport is in the formative stages, however evidence suggests 
that membrane transporters play a role in the movement of iAs and its methylated 
metabolites in and out of cells.  Membrane transporters that have been shown to participate in 
arsenic-transport in humans include; multidrug resistance-associated protein 1 and 2 (MRP-1, 
MRP-2), P-glycoprotein (P-gp), glucose transporter 1 (GLUT1), and aquaglyceroporin-7, -9 
(AQP7, AQP9).  AQP7, AQP9 and GLUT1 are bidirectional transporters that are believed to 
participate in the uptake of arsenicals while MRP-2 and P-gp have been shown to serve as 
exporters of arsenicals.  Indirect evidence suggests that arsenicals are exported from cells as 
arsenic-GSH complexes, presumably generated by various isoforms of glutathione-S-
transferase (GST), such as GST-μ, -θ, or -π.  Τhe activities of arsenic-transporters and GST 
isoforms can play a significant role in determining the distribution of arsenic metabolites in 
various target tissues.  Given that speciation greatly affects the reactivity of arsenic and plays 
a large role in determining the severity and character of its effects, the role of transporters in 
arsenic metabolism may be significant.  Importantly, arsenic transporters play a critical role 
in the elimination of arsenic from cells and subsequent excretion in the urine, feces and bile. 
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1.4.3 Metabolic Transformation of Arsenic 
 Upon ingestion, iAs is subject to two types of metabolic reactions:  1) the reduction of 
pentavalent arsenic (AsV) to trivalent arsenic (AsIII), and 2) the oxidative methylation of 
iAsIII, methylarsonous acid (MAsIII) and dimethylarsinous acid (DMAsIII).  The degree and 
efficiency with which these reactions take place is highly variable and greatly dependent on 
interspecies and interindividual differences.  The putative metabolic pathway for the 
metabolism of iAs by humans was first proposed by Frederick Challenger (26) and later 
revised by William Cullen (27).  As illustrated in Figure 1.4, arsenic metabolites are 
produced in a sequence of monomethylated, dimethylated, and trimethylated arsenical 
species.  In vivo demethylation of arsenic metabolites has not been reported in the literature.  
According to Figure 1.5, AsV species are reduced to AsIII before oxidative methylation.  This 
sequence is repeated to produce MAs, DMAs and in some organisms, trimethyl-As (TMAs), 
which can exist in either trivalent or pentavalent forms.  This section will provide an 
overview of these reactions and discuss their relative importance with respect to the 
metabolism and toxicity of ingested iAs.   
 Arsenic metabolism is an area of continued research because the biological effects of 
ingested arsenicals are strongly dependent on their metabolic transformation, especially with 
regards to oxidation and methylation status. For example, the trivalent arsenicals; iAsIII, 
MAsIII and DMAsIII, are more acutely toxic than their pentavalent counterparts; iAsV, 
methylarsonic acid (MAsV), and dimethylarsinic acid (DMAsV) (28).  Trivalent arsenicals 
have profound affinities toward sulfhydryl groups in peptides and proteins and their 
interaction with biologically active thiols is thought to underlie most of the adverse effects of 
arsenic.  Furthermore, iAsIII and its methylated metabolites, MAsIII and DMAsIII have been 
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demonstrated to act as potent cytotoxins, genotoxins, and enzyme inhibitors (29). Trivalent 
arsenicals have also been reported to interfere with major signal transduction pathways in 
human cells (30-32). 
+ 2e-
(iAsIII) arsenite
AsIIIO33-
(iAsV) arsenate
AsVO43-
Reduction
(MAsV) 
methylarsonic acid
CH3AsVO32-
(MAsIII) 
methylarsonous acid
CH3AsIIIO22-+ 2e-
(DMAsV) 
dimethylarsinic acid
(CH3)2AsVO2-
(DMAsIII) 
dimethylarsinous acid
(CH3)2AsIIIO-+ 2e-
(TMAsVO) 
trimethylarsine oxide
(CH3)3AsVO-
Methylation
Reduction
Methylation
Reduction
Methylation
(CH3)3AsIII
(TMAsIII) 
trimethylarsine
+ 2e- Reduction
 
Figure 1.4: Putative scheme for arsenic metabolism in mammals. 
 The in vivo reduction of arsenic in mammals was first reported in a study measuring 
arsenic speciation in the urine of rabbits injected with iAsV (0.04 mg/kg) (33).  The 
proportion of total-As excreted as iAsV was greatest immediately after injection and 
gradually decreased with time as the excretion of iAsIII progressively increased.  Similar 
results were obtained from studies using marmoset monkeys (34).  The non-enzymatic 
reduction of AsV-species to AsIII-species has been shown to occur in the presence of GSH, 
albeit at low rates (35).  Several AsV reductases have been proposed, including purine 
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nucleoside phosphorylase (PNP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and 
glutathione S-transferase-omega (GSTO).  The relevance of these enzymes with respect to in 
vivo arsenic metabolism is unclear.  PNP was proposed to be the AsV reductase present in rat 
liver cytosol (36); however, subsequent in vivo studies demonstrated that PNP is not essential 
for iAsV reduction in human erythrocytes or rats (37).  It has been reported that the 
ubiquitously expressed glycolytic enzyme, GAPDH, also acts as an iAsV reductase in human 
erythrocytes and isolated rat liver cytosol under in vitro conditions (36).  Confirmation of 
GAPDH as an iAsV reductase was hindered by in vivo studies in which inhibition of GAPDH 
activity in rats decreased iAsV reduction in the liver, but not in other tissues (38).  
Glutathione-S-transferase-omega (GSTO) has been hypothesized to function as a MAsV and 
DMAsV reductase in mammals (39,40); however establishment of the GSTO knockout 
mouse has demonstrated the limited relevance of this enzyme with respect to arsenic 
metabolism (41).  Based on these data, most, if not all, reduction of AsV-species is likely due 
to mechanisms not described above. 
 Arsenic methylation is a critical process in the metabolism of iAs.  In humans, 
ingested iAsV is methylated to produce MAs and DMAs.  In some animal species, TMAs is 
the final product.  Although some investigators have proposed that this series of reactions is 
performed by at least two distinct enzymes with separate reductive and methylative 
capacities (42), there is now sufficient evidence suggesting that both reactions are performed 
by a single enzyme, arsenic (+3 oxidation state) methyltransferase (AS3MT).  AS3MT is a 
42 kDa protein that was originally purified from the liver cytosol of adult male Fischer 344 
rats (43).  AS3MT mRNA has been detected in the heart, adrenals, urinary bladder, brain, 
kidneys, lungs and livers of rats, as well as cultured HepG2 cells (a human hepatocarcinoma 
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cell line) and primary human hepatocytes (43,44).  Interestingly, AS3MT mRNA has not 
been detected in UROtsa cells, a SV40 transformed human urothelial cell line that is 
incapable of producing methylated arsenicals (43).  Evidence supporting a role for AS3MT 
as an arsenic methyltransferase were obtained after cloning and preparation of the rat 
recombinant AS3MT (rrAS3MT), previously designated as cyt19.  rrAS3MT has been shown 
to catalyze the methylation of iAs to MAs, DMAs and TMAs species by utilizing 
physiological reductants, such as thioredoxin (TRx), and TR reductase (TR) and the methyl-
donor, S-adenosylmethionine (SAM) (45).  In these studies the conversion of iAsIII to its 
trivalent and pentavalent methylated metabolites was performed in the absence of other 
enzymes.  Thus, under these conditions, AS3MT catalyzes both AsV-reduction and AsIII 
methylation reactions.  The sufficiency of AS3MT to methylate arsenic was also 
demonstrated by the expression of AS3MT in UROtsa cells, a cell line without endogenous 
arsenic-methyltransferase activity (44).  UROtsa cells expressing AS3MT (UROtsa/F35) 
effectively methylated iAsIII to produce trivalent and pentavalent forms of MAs, and DMAs.  
In an alternative approach, RNA interference techniques were used to silence the endogenous 
expression of AS3MT in HepG2 cells to determine the contribution of AS3MT to their 
ability to methylate iAs (46).  In this study AS3MT mRNA and protein levels were decreased 
by 83 and 88%, respectively, resulting in a 70% decrease in iAs-methylation by HepG2 cells.  
Taken together these data provide strong evidence that AS3MT is sufficient for the 
methylation of iAs and is a key enzyme in the methylation pathway for iAs in human 
hepatocytes. 
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1.4.4 Arsenic Methylation Capacity 
 Numerous studies have documented the high degree of variability in arsenic 
methylation capacity in exposed humans and primary human cell lines.  Arsenic methylation 
capacity is the extent to which a cell, tissue, or organism is able to produce methylated 
arsenic species.  Although the specific factors responsible for the large interindividual 
variation in arsenic methylation capacity in humans have not been conclusively identified, a 
number of studies have suggested gender, ethnicity, genetics, diet and smoking as possible 
modifiers (47-49).  Emerging data has suggested a prominent role for single nucleotide 
polymorphisms (SNPs) in genes related to arsenic methylation such as AS3MT (49-51) and 
to a lesser extent, methylenetetrahydrofolate reductase (MTHFR) (47,49), an enzyme 
involved in folate metabolism and generation of SAM, the methyl-donor for arsenic 
methylation.  Folic acid supplementation has been undertaken in Bangladesh as a way to 
increase arsenic methylation capacity of individuals and decrease the occurrence and severity 
of arsenic-related diseases (52).  One study conducted in rodents has attempted to establish a 
role for folic acid and vitamin B12 in arsenic methylation (53), however this study used 
excessive, single doses of iAs thereby limiting the relevance of these findings to human 
populations that are chronically exposed to relatively low doses of iAs.  In addition to 
variability in “whole-body” arsenic methylation capacity, variable rates of methylation have 
also been demonstrated in primary human hepatocytes isolated from different human donors  
(54).  Examination of arsenic methylation rates in cultured primary human hepatocytes 
revealed up to a 7-fold difference between donors.  The specific cause of this variation has 
not been identified; however genetic polymorphisms, variable transporter activities, or 
cellular factors such as and TR and TRx may be responsible.   
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 Numerous studies have investigated the relationship between arsenic methylation 
capacity and health outcomes in exposed humans.  These studies are based primarily on 
analysis of urinary arsenic profiles of exposed individuals as a proxy for their methylation 
capacity.  It is important to note that the term “methylation capacity” used by many 
researchers in the field, is often used inaccurately in studies of urinary arsenic excretion.  
Some researchers estimate arsenic methylation capacity by measuring the primary 
methylation index (PMI), the ratio of MAs to iAs; or the secondary methylation index (SMI), 
the ratio of DMAs to MAs in the urine of exposed individuals (55).  However, measurement 
of urinary arsenic profiles is not an appropriate method for quantifying the methylation 
capacity of an organism because the variable retention of methylated arsenic metabolites by 
tissues is not taken into account.  Therefore it is unclear, from urinary arsenic profiles alone, 
if an exposed individual has a high methylation capacity or a low ability to retain methylated 
species in tissues.  Despite the inaccurate terminology, urinary arsenic profiles may be 
valuable when assessing disease risk in exposed individuals.  Given the important role of 
arsenic metabolism in disease susceptibility and severity in exposed populations, further 
investigation of the factors that influence arsenic methylation capacity is warranted. 
 
1.5 Health Effects of Arsenic Exposure 
 The contamination of groundwater supplies with naturally occurring arsenic has been 
documented in numerous countries throughout the world, including the United States (see 
section 1.3).  Inhabitants of these countries may be exposed to iAs in drinking-water 
exceeding 50 μg/L (6).  Numerous epidemiologic studies have associated chronic exposure to 
iAs with negative health effects including, increased prevalence of cancers of the skin, 
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urinary bladder, liver and lung (56-70).  Skin problems such as keratosis, hypopigmentation 
and hyperpigmentation (Fig. 1.5) are commonly found on individuals exposed to high 
concentrations of iAs in drinking-water in Taiwan, Bangladesh, West Bengal and Mexico.  
Data regarding the carcinogenic potential of arsenic has prompted the International Agency 
for Research on Cancer to classify iAs as a human carcinogen (71).  In a recent report by the 
National Research Council, it was concluded that the data obtained from epidemiological 
Keratosis of palms and soles
Hyperpigmentation of Skin
Hypopigmentation of 
Skin
Figure 1.5: Various skin abnorm-
alities suffered by residents of arsenic-
endemic regions of Banglaesh exposed 
to high levels of iAs in drinking-water.
Area of Inset Area of Inset
 
 
17
studies conducted in southwestern Taiwan demonstrating the dose-response relationship 
between cumulative arsenic exposure and risk of cancer, was sufficient to conduct 
quantitative risk assessments (72).  These risk assessments prompted various agencies, 
including the U. S. EPA, the WHO and Health Canada, to establish lower MCL’s for arsenic 
in drinking-water.  
 Despite the emphasis on the carcinogenic effects of chronic exposure to iAs, 
numerous studies have also demonstrated that iAs exerts other adverse health effects that do 
not involve the induction of cancer.  To date, non-cancerous disorders associated with 
chronic exposure to iAs include blackfoot disease, an occlusive disease of the peripheral 
vasculature (Fig. 1.6) (73), cardiovascular disease, cerebrovascular disease (74-80), 
hypertension (74), goiter (81), hepatomegaly (82), respiratory system dysfunction (83), 
diseases of the peripheral and central nervous systems (84-86) and diabetes mellitus (87-90).  
Risk of hypertension and diabetes mellitus have been suggested as the only non-cancerous 
diseases that exhibit a dose-response relationship to arsenic exposure.   
Figure 1.6:  Blackfoot disease suffered by residents of arsenic-endemic regions 
of Bangladesh and Taiwan exposed to high levels of iAs in drinking-water.  
 The dose response relationship between iAs exposure and disease risk demonstrate 
the potential of low-level iAs contamination of drinking-water supplies, possibly as low as 50 
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μg/L, to negatively impact human health.  Given the large number of people that are likely to 
consume water containing 50 μg/L or more of arsenic, the impact of arsenic exposure on 
public health may be unprecedented when compared to other environmental contaminants. 
 
1.5.1 Epidemiological Evidence Supporting Arsenic-Induced Diabetes 
The association between iAs exposure via drinking-water and increased risk of 
developing type 2 diabetes was first reported in a cross-sectional study conducted in Taiwan 
by Lai and associates (87).  These authors reported a two-fold increase in the prevalence of 
diabetes mellitus among residents of arseniasis-endemic areas as compared to residents in 
non-endemic areas.  Furthermore, a significant dose-response relationship was reported 
between cumulative exposure to iAs and the prevalence of diabetes.   The link between 
diabetes mellitus and consumption of water containing iAs was later confirmed by several 
cross-sectional and cohort studies from Taiwan (88,91) and Bangladesh (89,90).  Diagnosis 
of diabetes in the cohort studies was accomplished with oral glucose tolerance tests (OGTT) 
or death certificates while cross-sectional studies relied on the occurrence of glucosuria (the 
excretion of glucose in the urine), OGTT or information obtained from health records.  
Although these studies demonstrated an increased relative risk for diabetes in individuals 
exposed to high levels of arsenic, they failed to use biomarkers of arsenic exposure, such as 
urinary arsenic content.  Estimates of environmental arsenic intake were based on 
measurements of total arsenic levels in community drinking-water sources or proximity to 
areas endemic for arseniasis.   Other studies have examined the association between exposure 
to iAs in occupational settings and the occurrence of symptoms that are consistent with 
diabetes (92-94). These studies were retrospective in nature; therefore, arsenic exposure was 
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estimated indirectly based on assumptions of likely exposure given a particular occupation or 
job title.  The diagnosis of diabetes in these studies was done primarily using death 
certificates, although one study in Denmark used measurements of glycosylated hemoglobin 
as the diagnostic criterion (94).  In general, occupational studies failed to provide convincing 
support for the association observed in cross-sectional and cohort studies conducted in 
Taiwan and Bangladesh, possibly due to the relatively small study populations and the 
inability to accurately assess arsenic exposure in study subjects.   
It is evident that some of the epidemiologic studies linking chronic exposures to iAs 
with diabetes suffer problems associated with insufficient assessment of exposures to iAs, 
inadequate diagnosis of diabetes or lack of dose-response data. These methodological 
problems may limit the detection of the association between iAs exposure and diabetes in 
Taiwan and Bangladesh (95).  This conclusion may need to be revisited in light of a recent 
publication from Mexico (96).  Using data from their previous cross-sectional study, 
investigators designed a case-control study to evaluate the relationship between the 
consumption of iAs-containing drinking-water and diabetes.  To address the deficiencies of 
previous epidemiologic studies the investigators measured arsenic exposure directly in urine, 
while blood glucose measurements were used to diagnose diabetes according to criteria 
established by the American Diabetes Association.  Subjects with intermediate total arsenic 
concentrations in the urine (63.5 – 104 μg of arsenic/g of creatinine) had a two-fold higher 
risk of having diabetes, while the risk was nearly three times greater in subjects with higher 
concentrations of arsenic in urine (>104 μg of arsenic/g of creatinine).  This study is the first, 
outside of Taiwan or Bangladesh, to confirm the association between exposure to iAs in 
drinking-water and diabetes.  More importantly the association observed by these 
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investigators was seen in individuals exposed to relatively low concentrations of iAs in 
drinking-water (20 – 400 μg/L) as compared to subjects in Taiwan and Bangladesh, some of 
whom were exposed to as much as 1,600 μg/L of iAs. 
Currently the epidemiologic evidence supporting the association between arsenic 
exposure and diabetes is still a subject of debate (95).  Occupational studies have yielded 
mixed results of questionable validity.  In contrast, studies of iAs in drinking-water and 
diabetes, especially in Taiwan, Bangladesh and most recently, in Mexico, have provided 
substantial evidence for the association, thereby justifying further examination into the 
potential mechanisms responsible for the induction of diabetes.  In addition, laboratory 
studies have demonstrated the potential of iAs and its metabolites to interfere with processes 
and mechanisms related to glucose metabolism. 
 
1.5.2 Laboratory Studies of the Effects of Arsenic on Glucose Metabolism 
 A comprehensive discussion of laboratory studies that examine the effects of arsenic 
on glucose metabolism can be found in Chapter IV, sections 4.2.2 and 4.2.3 of this 
dissertation. 
 
1.5.3 Classification of Diabetes and Pathology 
 Studies examining the role of iAs exposure on the development of diabetes represent 
a growing area of research.  Diabetes refers to a group of metabolic diseases characterized by 
systemic disruption of glucose homeostasis.  Insulin-dependent (type 1) diabetes is caused by 
the autoimmune destruction of insulin-producing pancreatic β-cells, resulting in a severe 
deficiency of circulating insulin (hypoinsulinemia) and the concomitant elevation of blood 
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glucose (hyperglycemia).  Non-insulin-dependent (type 2) diabetes is characterized by 
hyperglycemia due to the resistance of peripheral tissues such as adipose tissue, skeletal 
muscle and the liver to an insulin stimulus and a relative increase in insulin production by 
pancreatic β-cells.  Gestational diabetes (type 3) is similar to type 2 diabetes with respect to 
its pathogenesis and clinical symptoms; however, it occurs in women during pregnancy and 
usually improves or disappears after childbirth.  The detailed pathogenesis of arsenic-induced 
diabetes is unknown.  Diagnosis of diabetes in populations exposed to iAs has relied 
primarily on measurements of fasting blood glucose, glucosuria, glycosylated hemoglobin 
(HbA1c), oral glucose tolerance tests, clinical history of the disease or mortality linked to 
diabetes.  The results of these diagnoses are suggestive of insulin resistance and type 2 
diabetes; however, β-cell dysfunction cannot be ruled out. 
 
 
22
  
CHAPTER II 
MOLECULAR MECHANISMS OF THE DIABETOGENIC EFFECTS OF ARSENIC: 
INHIBITION OF INSULIN SIGNALING BY ARSENITE AND                       
METHYLARSONOUS ACID 
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2.1 Abstract   
Background:  An increased prevalence of diabetes mellitus has been reported among 
individuals chronically exposed to inorganic arsenic (iAs).  However, mechanisms 
underlying the diabetogenic effects of iAs have not been characterized.  We have shown that 
trivalent metabolites of iAs inhibit insulin-stimulated glucose uptake in 3T3-L1 adipocytes 
by a mechanism that involves suppression of insulin-dependent phosphorylation of protein 
kinase B (PKB/Akt).   
Objectives:  The present study examined the effects of two of these metabolites, arsenite 
(iAsIII) and methylarsonous acid (MAsIII), on components of the insulin-activated signal 
transduction pathway that regulate PKB/Akt phosphorylation.   
Results:  Exposures to subtoxic concentrations of iAsIII or MAsIII had little or no effect on the 
activity of phosphatidylinositol 3-kinase (PI-3K), which synthesizes phosphatidylinositol-
3,4,5-triphosphate (PIP3) in response to insulin, or on phosphorylation of PTEN, a PIP3 
phosphatase.  Neither iAsIII nor MAsIII interfered with phosphorylation of 3-
phosphoinositide-dependent kinase-1 (PDK-1) located downstream from PI-3K.  However, 
PDK-1 activity was inhibited by both iAsIII and MAsIII.  Consistent with these findings, 
PDK-1-catalyzed phosphorylation of PKB/Akt(Thr308) and PKB/Akt activity were 
suppressed in exposed cells.  In addition, PKB/Akt(Ser473) phosphorylation, which is 
catalyzed by a putative PDK-2, was also suppressed.  MAsIII was considerably more potent 
than iAsIII as an inhibitor of PDK-1 activity and PKB/Akt phosphorylation.  Notably, 
expression of constitutively active PKB/Akt restored normal glucose uptake in insulin-
stimulated adipocytes treated with either iAsIII or MAsIII. 
Conclusions:  These results suggest that inhibition of the PDK-1/PKB/Akt-mediated 
transduction step is the key mechanism for the inhibition of glucose uptake in adipocytes 
exposed to iAsIII or MAsIII, and possibly for impaired glucose tolerance associated with 
human exposures to iAs.  
 
2.2 Introduction 
 Arsenic is a naturally occurring toxic metalloid and a potent human carcinogen (71).  
The cancer promoting effects of environmental exposures to inorganic arsenic (iAs) have 
been examined by epidemiological studies and in laboratory experiments.  Much less 
attention has been paid to the adverse effects of iAs that do not involve malignancies. 
Epidemiological evidence suggests that type 2 (non-insulin dependent) diabetes mellitus may 
be one of the most common non-cancerous diseases associated with chronic exposures to 
iAs.  Increased prevalences of type 2 diabetes or symptoms consistent with this disease have 
been associated with the consumption of drinking water containing high levels of iAs (74,87-
91,97,98) or with chronic exposures to iAs in occupational settings (92-94).  Although not all 
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epidemiological studies support the association between iAs exposure and diabetes (95), the 
existing evidence provides sufficient basis for investigation of the diabetogenic effects of 
iAs. 
 Type 2 diabetes is characterized by disruptions in whole-body glucose homeostasis 
due to insulin resistance and impaired glucose utilization by peripheral tissues, including 
skeletal muscle and adipose tissue.  The insulin-dependent activation of glucose uptake in 
these tissues is one of the key mechanisms that regulate glucose homeostasis.  The insulin-
activated signal transduction mechanism that stimulates glucose uptake by adipocytes has 
been extensively studied.  It includes the autophosphorylation of the β-subunit of the insulin 
receptor (IRβ) upon binding of insulin to the α-subunit of the receptor (IRα), the subsequent 
tyrosine phosphorylation of insulin receptor substrate 1 or 2 (IRS-1 or -2), and the binding of 
a phosphorylated IRS (p-IRS) to the regulatory (p85) subunit of the class IA 
phosphatidylinositol 3-kinase (PI-3K) that leads to the activation of its catalytic (p110) 
subunit.  The activated PI-3K catalyzes the phosphorylation of phosphatidylinositol-4,5-
bisphosphate (PIP2) at the plasma membrane to phosphatidylinositol-3,4,5-triphosphate 
(PIP3) (99-101).  PIP3 facilitates PDK-1/2 dependent phosphorylation/activation of PKB/Akt 
and two atypical enzymes of the protein kinase C (PKC) family, PKCλ and ζ (102-104). The 
phosphorylation of PKB/Akt results in the translocation of intracellular vesicles containing 
GLUT4 transporters from the perinuclear region to the plasma membrane and in the 
stimulation of glucose uptake (105,106). In addition to phosphorylated PKB/Akt (p-
PKB/Akt), phosphorylated PKCλ (p-PKCλ) and PKCζ (p-PKCζ) are thought to participate in 
the stimulation of GLUT4 translocation in response to insulin signaling (100,107).  The 
mechanism by which p-PKB/Akt, p-PKCλ and ζ induce the translocation and fusion of 
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GLUT4-containing vesicles with the plasma membrane, as well as the degree to which each 
of these kinases participates in this event, are unclear.  Recent studies have indicated that the 
PI-3K-dependent rearrangement of actin filaments (108) and activation of the microtubule-
associated motor protein kinesin (109) contribute to the translocation of GLUT4 to the 
plasma membrane.  The disruption of cytoskeletal components may represent a potential 
mechanism by which arsenic exposure inhibits ISGU.  Notably, arsenic has been shown to 
bind to actin and tubulin in human lymphoblastoid cells (110) and to inhibit the cytoskeletal 
protein synthesis in Swiss 3T3 mouse cells (111).  
 The mechanisms by which exposure to iAs may induce impaired glucose tolerance 
have not been systematically studied.  Data on the effects of arsenic on glucose homeostasis 
have been generated almost exclusively in studies that examined the metabolism of nutrients 
under severe stress induced by chemical or physical stimuli.  Results of in vitro studies have 
consistently shown significant increases in basal (insulin-independent) glucose uptake by 
various types of cells or dissected tissues exposed to cytotoxic concentrations of a trivalent 
iAs, arsenite (iAsIII), or an aromatic derivative of AsIII, phenylarsine oxide (PAO) (112-119).  
Consistent with these findings, some in vivo studies have reported moderate or severe 
hypoglycemia in animals chronically exposed to toxic, often lethal, concentrations of iAsIII or 
arsenate (iAsV), in drinking water (120-123).  Only limited information is available on the 
effects of low concentrations of arsenicals on glucose metabolism that are compatible with 
environmental or occupational exposures.  Micromolar concentrations of PAO have been 
shown to inhibit basal or insulin-stimulated glucose uptake (ISGU) by cultured cells 
(124,125) and by intact skeletal muscle (126,127).  PAO did not interfere with the insulin-
dependent phosphorylation of IRβ and did not interact directly with glucose transporters 
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(128,129).  The effects of physiologically relevant arsenicals on insulin-stimulated glucose 
metabolism have only recently been examined in this laboratory (32).  We have shown that 
iAsIII and the products of iAs methylation in humans, methylarsonous acid (MAsIII), and 
dimethylarsinous acid (DMAsIII) (29), inhibit ISGU by 3T3-L1 adipocytes at concentrations 
that do not affect cell viability.  Exposures to these arsenicals did not prevent IRβ and IRS 
phosphorylation or formation of the PI-3K/p-IRS complex.  However, both iAsIII and MAsIII 
inhibited the insulin-dependent phosphorylation of PKB/Akt that mediates ISGU in 
adipocytes. In contrast, DMAsIII did not inhibit PKB/Akt phosphorylation, suggesting that 
this metabolite of iAs inhibits ISGU by a PKB/Akt-independent mechanism. 
 The present study examined the molecular mechanisms of ISGU inhibition by iAsIII 
and MAsIII, focusing mainly on the components of the insulin-activated signal transduction 
pathway that regulate PKB/Akt phosphorylation in adipocytes.  Results of this work show 
that iAsIII and MAsIII inhibit PDK-1 activity, thus suppressing PDK-1-catalyzed 
phosphorylation of PKB/Akt and p-PKB/Akt-mediated translocation of GLUT4 transporters 
to the plasma membrane.  Notably, MAsIII was an order of magnitude more potent than iAsIII 
as an inhibitor of the PDK-1/PKB/Akt signal transduction step and of glucose uptake in 
insulin-stimulated adipocytes. Thus, the formation of MAsIII in the methylation pathway for 
iAs may play a critical role in determining the extent of the diabetogenic effects associated 
with chronic exposures to iAs.  
 
2.3 Materials and Methods 
2.3.1   Cell Culture and Treatment  
 3T3-L1 preadipocytes were obtained from Dr. Yashomati Patel (University of North 
Carolina, Greensboro).  Myr-PKB/Akt-3T3-L1 preadipocytes expressing constitutively 
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active PKB/Akt lacking the pleckstrin homology (PH) domain were provided by Dr. Scott 
Summers (University of Colorado at Boulder).  Addition of the src myristoylation sequence  
promotes constitutive membrane association and activation of PKB/Akt (105,130). A2myr-
PKB/Akt-3T3-L1 adipocytes, which express PKB/Akt containing a nonfunctional src 
myristoylation domain, and 3T3-L1 adipocytes containing the empty expression vector were 
also provided by Dr. Summers. All cell lines were cultured in Dulbecco's modified Eagle 
medium (Gibco, Grand Island, NY) with high glucose, 10% FBS (HyClone, Logan, UT), 
penicillin, and streptomycin (Sigma Chemical Co, St. Louis, MO).  Cells were cultured at 
37oC in a humidified incubator in a 90% air and 10% CO2 atmosphere. To induce 
differentiation, postconfluent cells were treated with a mixture of 0.5 mM 3-isobutyl-1-
methylxanthine, 1 µM dexamethasone, and 1 μg/ml insulin (all from Sigma Chemical Co.) 
for 48 hours and cultured in insulin-containing medium for an additional 48 hours (131). All 
experiments were performed between day 9 and day 12 post induction, when more than 90% 
of cells were fully differentiated.  Differentiated adipocytes were treated with iAsIII (sodium 
salt, Sigma Chemical Co.) or methylarsine oxide (provided by Dr. William Cullen, 
University of British Columbia, Vancouver, Canada).  Identity and purity of methylarsine 
oxide was confirmed by 1H-NMR and mass spectrometry.  In aqueous solutions, 
methylarsine oxide is hydrolyzed to form MAsIII (132).  Fresh stock solutions of iAsIII and 
MAsIII in sterile phosphate buffered saline (PBS) were prepared before each experiment to 
minimize the oxidation of iAsIII to iAsV or MAsIII to methylarsonic acid (MAsV).  Adipocytes 
were incubated with arsenicals or vehicle in a cell culture incubator for 4 hours.  
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 2.3.2 Glucose Uptake Assay  
 The glucose uptake assay followed the previously described procedures (131). 
Briefly, adipocytes were serum starved in the presence or absence of arsenicals for 4 h, 
washed with Krebs-Ringer Phosphate (KRP) buffer, and treated with 1 μM insulin at 37°C 
for 10 min.  Insulin activated cells were incubated for 10 minutes with 200 μM 2-[1-14C]-
deoxy-D-glucose (0.1 μCi/well) (NEN Life Science Products, Inc., Boston, MA).  To 
measure basal (insulin-independent) glucose uptake, cells were incubated with radiolabeled 
glucose without pretreatment with insulin.  After the incubation, cells were washed twice 
with PBS (0oC), and lysed in a solution of 0.5 N NaOH and 10% SDS. Radioactivity in cell 
lysates was measured, using a Wallac 1409 liquid scintillation counter (Wallac, Turku, 
Finland).  
   
2.3.3 Evaluation of Cytotoxic and Apoptotic Effects of Arsenicals 
 The MTT assay, which measures the conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) to purple formazan by mitochondrial dehydrogenases of 
viable cells (133), was used as previously described (32) to determine cell viability.  
Caspase-3 activity was examined in an assay mixture containing cell lysate and 
aminomethylcoumarin (AMC)-derived substrate, Z-DEVD-AMC (Molecular Probes, 
Carlsbad, CA). Cleavage of Z-DEVD-AMC by caspase-3 yields a blue-fluorescent product 
(excitation/emission wavelength = 342/441 nm) that was quantified by an HTS 7000 Bio 
Assay Reader (Perkin-Elmer, Norwalk, CT).  DNA fragmentation in adipocytes was 
examined by TUNEL.  For this assay, adipocytes were cultured on glass coverslips coated 
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with poly-L-lysine (Sigma Chemical Co.) and treated with arsenicals. Cells were then fixed 
in 4% buffered-paraformaldehyde and permeabilized in a solution of 0.1% Triton X-100 and 
0.1% sodium citrate (Sigma Chemical Co.).  DNA strand breaks were enzymatically labeled 
on 3’-OH termini with fluorescein-linked nucleotides, using the In Situ Cell Death Detection 
Kit (Roche Applied Science, Indianapolis, IN).  Nuclei of both normal and apoptotic cells 
were stained with 100 nM 4-6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma 
Chemical Co.).  Labeled cells were visualized using a Nikon Microphot FXA fluorescent 
microscope (Nikon, Tokyo, Japan). 
 
2.3.4 Immunofluorescent Analysis of GLUT-4  
 Adipocyte cultures on glass cover slips were treated with arsenicals, activated with 
insulin, and incubated with D-glucose (Sigma Chemical Co.).  After fixation with 4% 
buffered-paraformaldehyde, adipocytes were rinsed with ice-cold PBS and incubated with 
poly-L-lysine (0.5 mg/ml) for 1 min.  Cells were then treated with a hypotonic buffer (10 
mM HEPES (pH 7.5), 2 mM MgCl2, 23 mM KCl, 1 mM EDTA) and pulse sonicated for 5 
seconds in a sonication buffer (30 mM Hepes, pH 7.5, 6 mM MgCl2, 70 mM KCl, 3 mM 
EGTA, 1 mM dithiothreitol, 0.1 mM PMSF), using a Fisher Model 100 Sonic Dismembrator 
equipped with a 12.7 x 1.3 x 0.3 cm probe (Fisher Scientific, Hampton, NH).  Plasma 
membrane sheets attached to the coverslip were washed twice with the sonication buffer, 
incubated with an anti-GLUT4 antibody (Santa Cruz Biotech, Santa Cruz, CA) and labeled 
with Alexafluor 594 (Molecular Probes).  Fluorescent images were captured, using a Zeiss 
LSM 110 fluorescent microscope (Zeiss, Jena, Germany).  
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 2.3.5 Speciation Analysis of arsenic  
  Arsenicals in cell cultures exposed to iAsIII or MAsIII were analyzed by hydride 
generation atomic absorption spectrometry (HG-AAS) as previously described (134).  Cells 
and culture medium were analyzed separately for each treatment.  Arsines were generated at 
pH 1, cold-trapped, separated by their boiling points, and analyzed, using a Perkin-Elmer 
model 5100 PC atomic absorption spectrometer (Perkin-Elmer).  Under these conditions, 
arsines were generated from both AsIII and AsV species.  Thus, total iAs (iAs = iAsIII + iAsV), 
total methylarsenic (MAs = MAsIII + MAsV), and total dimethylarsenic (DMAs = DMAsIII + 
DMAsV) species were determined.  The identities of arsenicals in spectral peaks were 
confirmed using aliquots of samples spiked with standards. Calibration curves for each of the 
arsenicals (0.5, 2.5, 10, 20, 80 ng of arsenic) were generated to quantify results of the 
analyses. 
 
2.3.6 Immunoblot analyses  
 Protein extracts were prepared from cells treated with arsenicals, activated with 
insulin, and incubated with D-glucose, using a 25 mM Hepes (pH 7.4) lysis buffer containing 
1% NP-40, 100 mM NaCl, 2% glycerol, 5 mM sodium fluoride, 1 mM EDTA, 1 mM 
Na3VO4, 1 mM sodium pyrophosphate, 1 mM PMSF, 40 μg/ml aprotinin, 20 μg/ml 
leupeptin, and 20 μg/ml pepstatin (all from Sigma Chemical Co.).  Protein extracts were 
separated by 10% SDS-PAGE, electroblotted to Immobilon-P membranes (Millipore, 
Burlington, MA), and probed using the following antibodies: anti-p38 MAPK, anti-p-p38 
MAPK, anti-PKB/Akt, anti-p-PKB/Akt(Ser473) and anti-p-PKB/Akt(Thr308), anti-PTEN, 
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anti-p-PTEN(Ser380), anti-p-PDK-1(Ser241) (Cell Signaling Technology, Beverly, MA); 
anti-PI-3K(p85) (Upstate Biotechnology, Lake Placid, NY); anti-β-actin (Abcam, 
Cambridge, MA). The antigen-antibody complexes on immunoblots were treated with HRP-
conjugated secondary antibodies (Santa Cruz Biotechnology) and visualized using 
autoradiography or the Gene Gnome imaging system (Syngene, Frederick, MD). 
 
2.3.7 Protein Kinase Activity Assays 
  PI-3K, PKB/Akt and PDK-1 activities were measured in cell lysates from adipocytes 
treated with arsenicals and activated with insulin after immunoprecipitation with specific 
antibodies bound to protein G agarose beads (Santa Cruz Biotechnology).  For a single assay 
the immunoprecipitate from cells cultured in one 10-cm plate was used.   The assay 
conditions were as follows: 
 
PI-3K Assay  
 PI-3K was immunoprecipitated from control (untreated) adipocytes or from 
adipocytes exposed to arsenicals with an anti-phosphotyrosine (PY20) antibody.  PI-3K 
immunoprecipitated from insulin-activated adipocytes pretreated with 1 nM wortmannin (a 
specific inhibitor of PI-3K) was used as a negative control.  The enzyme activity was 
measured in a 50 μl assay mixture containing the immunoprecipitated PI-3K, 20 mM HEPES 
(pH 7.4), 50 mM MgCl2, 200 μM adenosine, 40 μM ATP (all from Sigma Chemical Co.), 20 
μCi [γ-32P]-ATP (NEN Life Science Products, Inc.), and L-α-phosphotidylinositol (PI) 
(Avanti Polar Lipids Inc., Alabaster, AL) as a substrate (Augustine et al. 1991).  The reaction 
was stopped by 1 N HCl.  A 30-minute incubation at 37oC of the assay mixture containing 
PI-3K from control cells resulted in the formation of radiolabeled phosphatidylinositol-
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phosphate (PIP) and phosphatidylinositol-bisphosphate (PIP2).  To simplify the analysis, a 
10-minute incubation that yielded only PIP was used throughout this study. Radiolabeled 
phospholipids were extracted in CHCl3:CH3OH (1:1).  The organic phase was washed with 
CH3OH:HCl (1:1), evaporated under N2, and the residue was dissolved in CHCl3:CH3OH 
(2:1).  The extract was separated by TLC on glass silica plates pretreated with 1% potassium 
oxalate, using an n-propanol:2 N acetic acid (65:35) solvent system (135).  The distribution 
of radioactivity on TLC plates was evaluated, using a computerized Fuji FLA-2000 imaging 
system (Fujifilm, Stamford, CT).  The following standards were used to confirm the identity 
of separated phospholipids: L-α-phosphatidylinositol, L-α-phosphatidylinositol-4-phosphate, 
L-α-phosphatidylinositol-4,5-bisphosphate (Avanti Polar Lipids Inc.).  Standards were 
visualized on developed TLC plates by treatment with 50% H2SO4 at 100oC for 1 h.   
 
PKB/Akt Assay 
 PKB/Akt activity was measured using an Akt1/PKBα Immunoprecipitation-Kinase 
Assay Kit (Upstate Biotechnology), following the manufacturer’s protocol.  PKB/Akt was 
immunoprecipitated with an antibody raised against the pleckstrin homology domain of 
PKB/Akt.  The assay mixture contained 20 mM MOPS (pH 7.2), 25 mM β-
glycerophosphate, 5 mM EGTA, 1 mM Na3VO4, 1 mM dithiothreitol, 10 mM PKA inhibitor 
peptide (Upstate Biotechnology), 19 mM MgCl2, 125 μM ATP, 5 μCi [γ-32P]-ATP, and 
Akt/SGK peptide as a substrate.  Incubation was carried out at 30oC for 10 min with 
continuous shaking.  The radiolabeled peptide was blotted on P81 phosphocellulose and 
quantified by liquid scintillation. 
 
PDK-1 Assay 
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 PDK-1 activity was measured using a PDK-1 Kinase Assay Kit (Upstate 
Biotechnology).  PDK-1 was immunoprecipitated with an anti-p-PDK-1(Ser241) antibody 
(Cell Signaling Technology).  The  assay mixture contained 50 mM Tris-HCl (pH 7.5), 0.1 
mM EGTA, 0.1 mM EDTA, 1 mM Tris(2-Carboxyethyl) phosphine, 25 μM PKA peptide 
inhibitor (Upstate Biotechnology), 1 μM microcystin-LR, 10 mM magnesium acetate, 15 
mM MgCl2, 100 μM ATP and 5 μCi [γ-32P]-ATP.  The assay was performed at 30oC in two 
incubation steps.  In the first 30-minute step, PDK-1 phosphorylates (activates) recombinant 
serum and glucocorticoid-induced protein kinase-1 (SGK1). In the second 10-minute step, 
the activated SGK1 phosphorylates a synthetic peptide (RPRAATF) using [γ-32P]-ATP as a 
phosphate donor. The radiolabeled peptide is blotted on P81 phosphocellulose and quantified 
by liquid scintillation. 
 
2.3.8 Statistical Analysis  
 All experiments were replicated to ensure the reproducibility of results.  
Representative findings are shown.  Results of the cell viability, glucose uptake and protein 
kinase activity assays were evaluated by ANOVA with Tukey multiple comparison posttest 
using a GraphPad Instat statistical software package (GraphPad Software, San Diego, CA).  
Differences among means with p value less than 0.05 were considered statistically 
significant. 
 
2.4 Results 
 Our previous work has shown that trivalent arsenicals inhibit ISGU by 3T3-L1 
adipocytes. However, the possible association between the inhibition of ISGU and a general 
loss of cell functions due to the cytotoxicity of arsenicals has not been thoroughly examined.  
In this study, we examined ISGU and cell viability in adipocytes exposed for 4 hours to iAsIII  
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or MAsIII at a wide range of concentrations.  Consistent with our previous report (32), 
stimulation of 3T3-L1 adipocytes with insulin increased glucose uptake by 9- to 11-fold over 
basal levels (data not shown).  ISGU was significantly inhibited by concentrations as low as 
5 μM iAsIII and 0.5 μM MAsIII (Fig. 1.1A, B).  In contrast, cell viability decreased only when 
concentrations of iAsIII and MAsIII exceeded 1 mM and 5 μM, respectively.  Gross 
abnormalities in adipocyte morphology were absent at all concentrations tested, although 
minor cell detachment did occur at higher concentrations (≥ 200 μM iAsIII and ≥ 10 μM 
MAsIII).  The estimated IC50 values for the inhibition of ISGU were 25 μM for iAsIII and 
4 μM for MAsIII.  In comparison, the LC50 values characterizing the cytotoxic effects were 11 
mM for iAsIII and 15 μM for MAsIII.  Thus, the inhibition of ISGU by iAsIII and MAsIII at or 
below IC50 values was not due to impaired adipocyte viability.  However, both iAsIII and 
MAsIII can induce cell apoptosis (136-138). At early stages, apoptotic processes may affect 
cell functions without having immediate effects on cell viability.  We examined apoptotic 
markers in adipocytes exposed for 4 hours to 50 μM iAsIII and 2 μM MAsIII, the 
concentrations that effectively inhibit ISGU, but are far below the minimal cytotoxic 
concentrations.  Under these exposure conditions, both iAsIII and MAsIII significantly 
increased the activity of caspase-3, an early marker of apoptosis (Fig. 1.2A).  Adipocytes 
treated with 500 µM H2O2 were used as positive controls for this experiment.  Pretreatment 
with 75 μM AC-DEVD-CHO, a cell-permeable caspase-3 inhibitor, prevented caspase-3 
activation by both arsenicals and by H2O2. However, pretreatment with AC-DEVD-CHO did 
not prevent the decrease in ISGU in cells treated with either iAsIII or MAsIII (Fig. 2.2B), 
suggesting that the inhibition of ISGU was independent of processes associated with early 
stages of apoptosis.  TUNEL was used to determine the degree of DNA fragmentation in 
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Figure 2.1:  iAsIII or MAsIII inhibit insulin-stimulated glucose uptake by adipocytes at 
concentrations that do not compromise cell viability. 3T3-L1 adipocytes were treated with 
(A) iAsIII or (B) MAsIII for 4 h.  [14C]-2-deoxyglucose uptake (closed circles) was assessed 
in treated and untreated (control) cells after a 10-min activation with insulin.  Cell viability 
(open circles) was measured by MTT assay.    Each value represents the mean ± SD, n = 
3-5, *Statistically significant differences (p<0.05) between treated and control cells.  The 
concentrations of 50 μM iAsIII and 2 μM MAsIII (indicated by arrows) were used in all 
subsequent experiments. 
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adipocytes exposed to 50 μM iAsIII or 2 μM MAsIII (Fig. 2.3).  Adipocyte nuclei were stained 
with DAPI to determine the total number of cells (data not shown).  The average apoptotic 
index (percentage of TUNEL-positive cells) was about 16% for control adipocytes and did 
not change after a 4-h exposure to either iAsIII or MAsIII.  However, the apoptotic index 
increased considerably after longer exposure times, reaching  an average of 32% for iAsIII 
and 39% for MAsIII after 24 hours and more than 90% after 72-h exposure to either arsenical.  
These data suggest that 4-h exposures to 50 μM iAsIII or 2 μM MAsIII did not compromise 
cell viability or integrity.  In addition, neither 50 μM iAsIII nor 2 μM MAsIII induced p38 
MAPK phosphorylation during the 4-h exposure (data not shown).  Therefore, the inhibition 
of ISGU is not associated with stress and is likely due to specific effects of these arsenicals 
on mediators of insulin signaling or on the cellular components involved in glucose transport.  
Based on these results 4-h exposures to 50 μM iAsIII and 2 μM MAsIII were used in further 
experiments to examine the effects of iAsIII or MAsIII on components of the insulin-activated 
signal transduction pathway in 3T3-L1 adipocytes.   
 The effects of iAsIII or MAsIII on mediators of insulin signaling would ultimately 
depend on the intracellular concentrations and metabolic conversion of these arsenicals.  We 
examined the distribution of arsenic species in adipocytes after a 4-h exposure to iAsIII or 
MAsIII, using HG-AAS.  Cells exposed to 50 μM iAsIII retained about 3 times more arsenic 
than cells exposed to 2 μM MAsIII (Fig. 2.4).  Retained arsenic represented 2.5% and 16% of 
the total arsenic in cultures exposed to iAsIII or MAsIII, respectively.  Only iAs and MAs 
species were detected in adipocyte cultures exposed to iAsIII and MAsIII, respectively, 
indicating that no methylation conversion took place during the 4-h exposures.  These 
 
 
37
Figure 2.2:  Inhibition of insulin-stimulated glucose uptake in adipocytes exposed to 
subtoxic concentrations of iAsIII or MAsIII are independent of caspase-3 activation.  (A) 
Caspase-3 activity was measured in 3T3-L1 adipocytes treated for 4 h with 50 μM iAsIII or 
2 μM MAsIII and in untreated (control) cells in the presence (open bar) or absence (closed 
bar) of 75 μM AC-DEVD-CHO, a caspase-3 inhibitor.  Adipocytes treated with 500 μM 
H2O2 for 4 h were used as positive controls.  (B) Basal and insulin-stimulated uptake of 
[14C]-2-deoxyglucose was measured in adipocytes exposed for 4 h to 50 μM iAsIII or 2 μM 
MAsIII in the presence (open bar) or absence (closed bar) of 75 μM AC-DEVD-CHO. Each 
value represents the mean ± SD, n = 3-5, *Statistically significant differences (p<0.05)
between treated and untreated (control) cells.
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Figure 2.3:  Four-hour exposures to subtoxic concentrations of iAsIII or MAsIII do not 
increase DNA fragmentation in cultured adipocytes.  DNA fragmentation was measured 
by TUNEL in 3T3-L1 adipocytes treated with 50 μM iAsIII or 2 μM MAsIII for 4, 24, 48, 
and 72 h.  Untreated adipocytes were used as controls.  Color images show green 
fluorescein signal of fragmented DNA in apoptotic cells.  Gray-scale images illustrate the 
corresponding cell morphology. Magnification, 10x. Bars = 40 μM (Representative fields 
of 2 independent experiments are shown.)  
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findings are consistent with previous reports that found adipocytes to be inefficient 
methylators of iAs (32). 
 The translocation of GLUT4 from the perinuclear compartment to the plasma 
membrane is a prerequisite for glucose uptake in adipocytes stimulated with insulin.  
Immunofluorescent staining  was used in this study to examine the association of GLUT4 
with the plasma membranes of insulin-stimulated 3T3-L1 adipocytes treated with 50 μM 
iAsIII or 2 μM MAsIII for 4 hours and from control (untreated) cells that were or were not 
stimulated with insulin (Fig. 2.5).  Stimulation with insulin dramatically increased the 
GLUT4-specific fluorescent signal in plasma membrane lawns of control cells.  GLUT4 
signals in plasma membrane lawns isolated from insulin-stimulated cells treated with either 
iAsIII or MAsIII were noticeably weaker as compared to control insulin-stimulated cells, 
suggesting that both arsenicals interfered with the translocation of GLUT4 in response to 
insulin stimulation.  
 The impaired ISGU in adipocytes exposed to trivalent arsenicals has previously been 
linked to the inhibition of components of the insulin signal transduction pathway located 
downstream of IRS1/2, but upstream of PKB/Akt (32).  PI-3K is located downstream of IRS.  
The binding of p-IRS to the regulatory (p85) subunit of PI-3K in response to insulin 
stimulates the PI-3K-catalyzed production of PIP3 from PIP2.  In this study, the association of 
p-IRS with PI-3K was examined in insulin-stimulated adipocytes exposed for 4 hours to 50 
μM iAsIII or 2 μM MAsIII.  Neither iAsIII nor MAsIII affected the amount of PI-3K (p85), 
immunoprecipitated with an anti-phosphotyrosine (PY20) antibody, which reacts with 
phosphorylated tyrosine residues of IRS in the insulin-activated PI-3K complex (Fig. 2.6A).  
PI-3K activity was measured in adipocytes exposed for 4 hours to 50 or 100 μM iAsIII or to 2 
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Figure 2.4:  Retention of arsenic species in 3T3-L1 adipocytes exposed to iAsIII or 
MAsIII.  Arsenic species retained in 3T3-L1 adipocytes exposed for 4 h to 50 μM iAsIII
or 2 μM MAsIII were analyzed by hydride generation-atomic absorption spectrometry 
(HG-AAS): (closed bar) iAsIII + iAsV; (hatched bar) MAsIII + MAsV. (Note: The HG-
AAS technique used in this study cannot distinguish between AsIII and AsV species.) 
Each value represents the mean ± SD, n = 3.    
Figure 2.5:  Exposures to subtoxic concentrations of iAsIII or MAsIII inhibit GLUT4 
association with the plasma membrane of insulin-activated adipocytes.  Immuno-
fluorescent images of GLUT4 in plasma membrane lawns isolated from control 
(untreated) 3T3-L1 adipocytes (A) before and (B) after activation with insulin and from 
insulin-activated adipocytes treated for 4 h with (C) 50 μM iAsIII or (D) 2 μM MAsIII. 
Adipocytes were fixed and sonicated to prepare plasma membrane lawns. GLUT4 was 
labeled with an anti-GLUT4 antibody and visualized with a fluorescent secondary 
antibody. Magnification 40x. Bars = 10 μM.  (Representative fields of 2 independent 
experiments are shown.) 
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or 5 μM MAsIII.  Exposures to iAsIII had no effect on PI-3K activity.  A relatively small 
decrease in PI-3K activity was detected in cells exposed to 2 μM MAsIII, however, no 
changes were found in cells exposed to 5 μM MAsIII (data not shown).  Effects of MAsIII on 
PI-3K activity were further analyzed in an in vitro assay mixture containing PI-3K 
immunoprecipitated from control insulin-stimulated adipocytes.  Addition of MAsIII into this 
mixture at concentrations up to 50 μM did not inhibit PI-3K activity (data not shown).  
PTEN, a PIP3 phosphatase, is involved in the regulation of PIP3 levels in adipocytes.  PTEN 
activity is regulated by a casein kinase 2-catalyzed phosphorylation on its C-terminal 
noncatalytic regulatory domain, which includes Ser380 (139). Neither 50 μM iAsIII nor 2 μM 
MAsIII altered the levels of total PTEN or pPTEN(Ser380) (Fig. 2.6A).  No changes in the 
ratio of phosphorylated pPTEN(Ser380) to total PTEN were found in insulin-stimulated 
adipocytes exposed to either iAsIII nor MAsIII (Fig. 2.6B). 
 Phosphorylation on Ser241 is required for optimal activity of PDK-1, a downstream 
effector of PI-3K (140).  Figure 2.7A shows that exposures to 50 μM iAsIII or 2 μM MAsIII 
had no significant effects on the level of Ser241-phosphorylated PDK-1 in insulin-stimulated 
adipocytes.  However, PDK-1 activity was significantly lower in cells exposed to either iAsIII 
or MAsIII, 47% and 57% of that in control cells, respectively (Fig. 2.7B). 
 In the insulin-activated signal transduction pathway, PKB/Akt is the downstream 
effector of PDK-1. The activation of PKB/Akt in response to insulin stimulation includes the 
phosphorylation of Ser473 and Thr308 residues (141). Our previous work demonstrated that 
exposures to iAsIII or MAsIII inhibit PKB/Akt phosphorylation on Ser473 (32) which is 
thought to be catalyzed by a putative Ser-kinase, PDK-2 (141).  PDK-1 is responsible for 
Thr308 phosphorylation, which is required for maximal PKB/Akt activity (142).   
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Figure 2.6:  Exposures to subtoxic concentrations of iAsIII or MAsIII do not affect insulin 
signal mediators that regulate phosphatidylinositol 3, 4, 5-triphosphate levels in insulin-
activated adipocytes.  (A)  Immunoblot analyses of the activated phosphatidylinositol 3-
kinase (PI-3K), total PTEN, and Ser380-phosphorylated PTEN in control 3T3-L1 
adipocytes before or after activation with insulin and in insulin-activated adipocytes treated 
for 4 h with 50 μM iAsIII or 2 μM MAsIII.  Activated PI-3K was immunoprecipitated from 
control and exposed cells with an anti-phospho-Tyr (PY20) antibody and immunoblotted 
with an antibody against the regulatory (p85) subunit.  (Representative blots of 3 
independent experiments are shown.) (B) The ratio of Ser380-phosphorylated PTEN to total 
PTEN expressed as a percent of the ratio found in control adipocytes prior to activation 
with insulin. Each value represents the mean ± SD, n = 3.
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Figure 2.7:  Exposures to subtoxic concentrations of iAsIII or MAsIII do not affect the 
phosphorylation of phosphoinositide-dependent protein kinase-1 (PDK-1), but inhibit 
PDK-1 activity in adipocytes.  (A) Immunoblot analysis of Ser241-phosphorylated PDK-1 
in insulin-activated 3T3-L1 adipocytes treated for 4 h with 50 μM iAsIII or 2 μM MAsIII
and in control (untreated) insulin-activated adipocytes, (Representative blot of 3 
independent experiments is shown). (B) The kinase activity of PDK-1 immunoprecipitated 
from insulin-activated control or treated 3T3-L1 adipocytes.  Each value represents the 
mean ± SD, n = 4-5. *Statistically significant differences (p<0.05) between treated and 
control cells. 
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 Immunoblot analysis carried out in this study showed that 4-h exposures to 50 μM iAsIII or 2 
μM MAsIII inhibited the insulin-dependent phosphorylation of PKB/Akt on both Ser473 and 
Thr308 residues (Fig. 2.8A).  PKB/Akt activity in insulin-stimulated adipocytes exposed to 
iAsIII and MAsIII was 47% and 28% of that in control insulin-activated cells, respectively 
(Fig. 2.8B).   
 To further evaluate the role of the PDK-1/PKB/Akt signal transduction step as a 
target for trivalent arsenicals in the insulin-activated signal transduction pathway, we 
examined the effects of iAsIII or MAsIII on ISGU by adipocytes expressing constitutively 
active myr-PKB/Akt.  Adipocytes expressing an inactive A2myr-PKB/Akt mutant or empty 
expression vector were used as negative controls.  Consistent with the constitutive activation 
of PKB/Akt, glucose uptake by adipocytes expressing myr-PKB/Akt was elevated even in 
the absence of insulin stimulation (Fig. 2.9).  Four-hour exposures to 50 μM iAsIII or 2 μM 
MAsIII had no effect on ISGU by myr-PKB/Akt expressing cells.  In contrast, both arsenicals 
inhibited ISGU in cells expressing the inactive A2myr-PKB/Akt mutant or the empty 
expression vector.  
 
2.5 Discussion 
 Previous studies have shown that AsIII-containing species may affect glucose uptake 
by cultured cells or dissected tissues by two independent mechanisms that strictly depend on 
the concentration of AsIII.  Highly-toxic concentrations of AsIII stimulate glucose uptake in 
the absence of insulin (112-119) through a mechanism that involves activation of p38 
MAPK-mediated stress signaling and PI-3K-dependent phosphorylation of PKB/Akt (143).  
In our experiments exposure of 3T3-L1 adipocytes to 50 μM iAsIII and 2 μM MAsIII for 4 h  
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 Figure 2.8.  Exposures to subtoxic concentrations of iAsIII or MAsIII inhibit the 
phosphorylation and activity of PKB/Akt. (A) Immunoblot analysis of total PKB/Akt and 
Ser473- or Thr308-phosphorylated PKB/Akt in insulin-activated 3T3-L1 adipocytes 
treated for 4 h with 50 μM iAsIII or 2 μM MAsIII and in insulin-activated control 
(untreated) cells, (Representative blots of 3 independent experiments are shown.)  (B) The 
activity of PKB/Akt immuno-precipitated from insulin-activated control and treated 
adipocytes. Each value represents the mean ± SD, n = 4-5. *Statistically significant 
differences (p<0.05) between treated and control cells.
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Figure 2.9:  Constitutive activation of PKB/Akt prevents the inhibition of insulin-
stimulated glucose uptake in adipocytes treated with subtoxic concentrations of iAsIII or 
MAsIII.  Basal and insulin-stimulated [14C]-2-deoxyglucose uptake by 3T3-L1 adipocytes 
treated for 4 h with 50 μM iAsIII or 2 μM MAsIII and by untreated adipocytes expressing a 
constitutively active myristoylated PKB/Akt (myr-PKB/Akt) (closed bar), an inactive 
PKB/Akt mutant (A2myr-PKB/Akt) (hatched bar), or an empty expression vector (open 
bar).  Each value represents the mean ± SD, n = 4-5. *Statistically significant differences 
(p<0.05) between treated and control cells.  
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did not activate p38 MAPK, thus providing further evidence of the subtoxic nature of our 
exposure conditions. Treatments with toxic concentrations of arsenicals are not comparable 
to environmental or occupational exposures to iAs that do not typically induce acute stress or 
tissue damage.  In contrast, subtoxic concentrations of AsIII inhibit ISGU (124-127) in a 
manner that is consistent with impaired glucose tolerance reported among individuals 
chronically exposed to relatively low concentrations of iAs.    We have shown that inhibition 
of ISGU in adipocytes exposed to subtoxic concentrations of trivalent metabolites of iAs, 
iAsIII or MAsIII, is associated with the suppression of PKB/Akt phosphorylation (32).  
Because neither iAsIII nor MAsIII interfered with insulin signaling upstream of PI-3K (32), 
the present work focused on the signal transduction steps immediately preceding PKB/Akt 
phosphorylation, specifically, on the enzymatic system controlling PIP3 levels in insulin-
activated cells and on PDK-1.   
 The formation of PIP3 catalyzed by the insulin-activated PI-3K/IRS complex is an 
essential step in ISGU by adipocytes.  PIP3 is required for PDK-1 catalyzed phosphorylation 
of PKB/Akt on Thr308 (140).  PIP3 is thought to interact directly with the PH-domain of 
PDK-1 and PKB/Akt, activating PDK-1 or facilitating Thr308 phosphorylation of PKB/Akt.  
Other studies suggest that PIP3 promotes the phosphorylation of PKB/Akt on Ser473 by a 
putative PDK-2, thereby priming PKB/Akt for PDK-1-catalyzed phosphorylation of Thr308 
(141).  PIP3 concentration in the membrane region of cells is subjected to strict regulation 
involving PI-3K and specific lipid phosphatases, including PTEN (phosphatase and tensin 
homolog deleted on chromosome ten) (144) and SHIP2 (Src homology 2-containing inositol 
5'-phosphatase 2) (145).  Both PTEN, a D-3 lipid phosphatase, and SHIP2, a D-5 lipid 
phosphatase, are expressed in adipocytes.  However, a recent report suggests that only PTEN 
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is capable of suppressing insulin signaling in 3T3-L1 adipocytes (146).  PTEN is 
phosphorylated on Ser380 and Thr382/383 by casein kinase 2 (139).  The phosphorylated 
PTEN (p-PTEN) is less susceptible to degradation by the proteosome, but is less active. 
Inhibition of Ser380 phosphorylation increases PTEN activity, but destabilizes the enzyme 
(147,148).  Factors that interfere with PI-3K activation in response to insulin or inhibit PTEN 
phosphorylation may decrease PIP3 levels in adipocytes and, ultimately, prevent PDK-1/2-
catalyzed phosphorylation of PKB/Akt.   
 In this study, iAsIII and MAsIII inhibited PDK-1/2 catalyzed phosphorylation of 
PKB/Akt on Thr308 and Ser473, but had little or no effect on PI-3K activity or PTEN 
phosphorylation.  In addition, neither iAsIII nor MAsIII affected PDK-1(Ser241) 
phosphorylation, which is essential for PDK-1 activity.  These results suggest that iAsIII and 
MAsIII inhibit PDK-1 activity through direct interactions with the enzyme.  Sulfhydryl 
groups of vicinal or closely-spaced cysteines are typical high-affinity targets for trivalent 
arsenicals in protein structures (149-154).  Two such closely-spaced cysteines (Cys21 and 
Cys23) are present in the N-terminus of both mouse and human PDK-1 (155,156).  Thus, it is 
plausible that binding of iAsIII and MAsIII to Cys21 and Cys23 is the proximate cause of 
PDK-1 inhibition by these arsenicals.  However, unlike MAsIII, which can form a stable 
cyclic structure with two thiols, iAsIII may require three coordination bonds to form a stable 
enzyme-inhibitor complex.  A lower affinity for binding to Cys21 and Cys23 may explain 
why iAsIII is a weaker inhibitor of PDK-1 than MAsIII.  In addition, the difference in 
potencies of iAsIII and MAsIII to inhibit PDK-1 activity and ISGU may be in part due to 
differences in the uptake and/or retention of these arsenicals by adipocytes. Our data suggest 
that MAsIII was retained by 3T3-L1 adipocytes more efficiently than iAsIII. These findings 
 
 
49
are consistent with the results of previous studies in other cell types (44,157).  Importantly, 
our data show that the expression of constitutively active myrPKB/Akt prevents the 
inhibition of ISGU by either iAsIII or MAsIII.  These data provide further evidence that the 
inhibition of ISGU by 3T3-L1 adipocytes exposed to iAsIII and MAsIII is due to the inhibition 
of the PDK-1-catalyzed activation of PKB/Akt and that neither iAsIII nor MAsIII disrupt 
signal transduction steps downstream from PDK-1/PKB/Akt, or events associated with 
GLUT4 translocation to the plasma membrane.   
 In summary, subtoxic concentrations of iAsIII and MAsIII inhibit ISGU by 3T3-L1 
adipocytes through a mechanism that involves the inhibition of PDK-1 activity and of PDK-
1/2-catalyzed phosphorylation of PKB/Akt (Fig. 2.10).  The inhibition of ISGU by iAsIII and 
MAsIII, trivalent metabolites of iAs, is consistent with impaired glucose tolerance reported in 
individuals chronically exposed to iAs from the environment.  In addition, the concentrations 
of iAsIII and MAsIII that inhibit ISGU by cultured adipocytes (as low as 5 and 0.5 µM, 
respectively) appear to be compatible with this type of exposure.  Thus, taken together, this 
work provides a mechanistic basis for the diabetogenic effects of chronic environmental and 
occupational exposures to iAs. 
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Figure 2.10:  The molecular mechanism underlying the inhibition of insulin-stimulated 
glucose uptake by adipocytes exposed to iAsIII or MAsIII.  The inhibition of PDK-1 and 
putative PDK-2 activities by iAsIII and MAsIII results in suppression of the downstream 
signaling steps, including PKB/Akt phosphorylation and GLUT4 translocation to the 
plasma membrane. 
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CHAPTER III 
MOLECULAR MECHANISMS OF THE DIABETOGENIC EFFECTS OF ARSENIC:  
INHIBITION OF INSULIN SIGNALING BY DIMETHYLARSINOUS ACID 
 
3.1 Introduction 
 The work presented in this chapter focuses on determining the molecular mechanisms 
that are responsible for the inhibition of ISGU in 3T3-L1 adipocytes that have been exposed 
to subtoxic concentrations of DMAsIII.  Data regarding the effects of DMAsIII on ISGU in 
adipocytes were not included in the published manuscript presented in Chapter II due to 
unpredictable variations encountered when assessing the activities of PDK-1 and PKB/Akt.  
The source of these variations remains unidentified; however we believe that the chemical 
instability of DMAsIII, may have contributed to our inability to achieve reproducible 
measures of PDK-1 and PKB/Akt activity.  In this chapter we present only data that were 
reproducible and are representative of the true effects of DMAsIII on ISGU and components 
of the insulin signal transduction pathway in 3T3-L1 adipocytes.   
  
3.2 Results 
3.2.1 DMAsIII Inhibits ISGU by 3T3-L1 Adipocytes at Sub-Toxic Concentrations 
 As reported in the previous chapter, stimulation of 3T3-L1 adipocytes with insulin 
increased glucose uptake by 9- to 11-fold over basal levels (data not shown).  Similarly to 
iAsIII and MAsIII, DMAsIII also inhibits ISGU by 3T3-L1 adipocytes.  Adipocytes exposed to 
as little as 5 μM DMAsIII for 4 h, followed by stimulation with insulin, exhibited a significant 
impairment of ISGU compared to stimulated control adipocytes (Fig. 3.1).  The estimated 
IC50 value for the inhibition of ISGU by DMAsIII was 10 μM, while the LC50 was 
approximately 35 μM.  These data suggest that the inhibition of ISGU by DMAsIII at or 
below the IC50 concentration of 10 μM was not due to non-specific cytotoxic events or 
impaired adipocyte viability.  Significant changes in cell morphology were noted in 
adipocytes exposed to DMAsIII, but only at concentrations exceeding 100 μM.  Cell 
detachment was also noted in adipocyte cultures treated with DMAsIII at or exceeding 1 mM. 
 
3.2.2 Impairment of ISGU by DMAsIII is Related to the Inhibition of GLUT4 Translocation 
 The translocation of GLUT4-containing vesicles from the perinuclear region to the 
plasma membrane is a critical process in ISGU by insulin-sensitive tissues.  
Immunofluorescent microscopy was used to study the effects of DMAsIII on the translocation 
of GLUT4 to the plasma membrane of insulin-stimulated 3T3-L1 adipocytes (Fig. 3.2).  
Stimulation with insulin significantly increased the GLUT4-specific fluorescent signal in 
plasma membrane lawns isolated from control cells, whereas GLUT4 staining was noticeably 
weaker in plasma membrane lawns isolated from cells exposed to 5 μM DMAsIII for 4 h.  
These data suggest that DMAsIII, like iAsIII and MAsIII, inhibits ISGU in exposed adipocytes 
by interfering with the insulin-mediated translocation of GLUT4 to the plasma membrane.   
 
3.2.3 DMAsIII is Retained but not Methylated by 3T3-L1 Adipocytes  
 The effects of DMAsIII on ISGU and GLUT4 translocation should be related to the 
intracellular concentrations and metabolic conversion of these arsenicals.  The retention and 
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Figure 3.1:  DMAsIII inhibits insulin-stimulated glucose uptake by adipocytes at 
concentrations that do not compromise cell viability. 3T3-L1 adipocytes were treated 
with DMAsIII 4 h.  [14C]-2-deoxyglucose uptake (closed circles) was assessed in 
treated and untreated (control) cells after a 10-min activation with insulin.  Cell 
viability (open circles) was measured by MTT assay.    Values represent the mean ± 
SD, Glucose uptake, n = 3-5; MTT, n = 1; *Statistically significant differences 
(p<0.05) between treated and control cells. 
 
Figure 3.2:  Exposures to subtoxic concentrations of DMAsIII inhibit GLUT4 association 
with the plasma membrane of insulin-activated adipocytes.  Immunofluorescent images of 
GLUT4 in plasma membrane lawns isolated from control (untreated) 3T3-L1 adipocytes 
(A) before and (B) after activation with insulin and from insulin-activated adipocytes 
treated for 4 h with (C) 5 μM DMAsIII. Adipocytes were fixed and sonicated to prepare 
plasma membrane lawns. GLUT4 was labeled with an anti-GLUT4 antibody and 
visualized with a fluorescent secondary antibody. Magnification 40x. Bars = 10 μM. 
(Representative fields of 2 independent experiments are shown.) 
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conversion of arsenic species in 3T3-L1 adipocytes after a 4-hr exposure to DMAsIII was 
examined using HG-AAS (Fig. 3.3).  Data on iAsIII and MAsIII were reported in Chapter II, 
however it is interesting to note that nearly 30% of DMAsIII added to the cultures was 
retained by the cells as compared to 2.5% of iAsIII and 16% of MAsIII.  Although some 
species have been shown to methylate DMAs to TMAsO (158), no TMAsO was detected in 
3T3-L1 cultures exposed to DMAsIII for 4-hours.   
 
3.2.4 DMAsIII Inhibits ISGU Independently of PKB/Akt Phosphorylation 
 The effects of arsenic on the insulin signal transduction pathway are a point of focus 
for our studies because of the central role this pathway plays in regulating ISGU in 
adipocytes and skeletal muscle.  We previously reported that 4-hr exposures to iAsIII, MAsIII 
and DMAsIII do not impact the phosphorylation of the β-chain of the insulin receptor, the 
downstream phosphorylation of IRS-1/2 or the formation of the IRS/PI-3K complex (32).  
However, the effects of these arsenicals on components of the insulin-signal transduction 
pathway diverge with respect to the phosphorylation of PKB/Akt.  As reported in the Chapter 
II, immunoblot analysis showed that 4-hr exposures to 50 μM iAsIII and 2 μM MAsIII 
inhibited the insulin-dependent phosphorylation of PKB/Akt on both Ser473 and Thr308 
residues; this is in contrast to exposure to 5 μM DMAsIII, which had little or no effect on the 
expression or phosphorylation of PKB/Akt (Fig. 3.4).  To further examine the role of 
PKB/Akt in the inhibition of ISGU by DMAsIII we exposed 3T3-L1 adipocytes expressing 
constitutively active myr-PKB/Akt to 5 μM DMAsIII for 4-hr and measured ISGU. 
Adipocytes expressing an inactive A2myr-PKB/Akt mutant or empty expression vector were 
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Figure 3.3:  Retention of arsenic species in 3T3-L1 adipocytes exposed to iAsIII, 
MAsIII or DMAsIII.  Arsenic species retained in 3T3-L1 adipocytes exposed for 4 h to 
50 μM iAsIII, 2 μM MAsIII, or 5 μM DMAsIII were analyzed by hydride generation-
atomic absorption spectrometry (HG-AAS): (closed bar) iAsIII + iAsV; (hatched bar) 
MAsIII + MAsV, (open bar) DMAsIII + DMAsV (Note: The HG-AAS technique used in 
this study cannot distinguish between AsIII and AsV species.) Each value represents the 
mean ± SD, n = 3 
Figure 3.4:  Exposures to subtoxic concentrations DMAsIII have little or no effect on the 
phosphorylation of protein kinase B (PKB/Akt). Immunoblot analysis of total PKB/Akt 
and Ser473- or Thr308-phosphorylated PKB/Akt in insulin-activated 3T3-L1 adipocytes 
treated for 4 h with 50 μM iAsIII, 2 μM MAsIII, and 5 μM DMAsIII in insulin-activated 
control (untreated) cells, (Representative blots of 3 independent experiments are shown.)
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used as negative controls.  Glucose uptake by myr-PKB/Akt expressing adipocytes was 
elevated even in the absence of insulin stimulation (Fig. 3.5).  Four-hour exposure to 5 μM 
DMAsIII significantly inhibited ISGU by myr-PKB/Akt expressing cells whereas exposures 
to 50 μM iAsIII and 2 μM MAsIII did not inhibit ISGU by this cell line.  Four-hour exposures 
to 5μM DMAsIII resulted in significant inhibition of ISGU by 3T3-L1 adipocytes expressing 
the A2myr-PKB/Akt or the empty expression vector.     
 
3.3 Discussion 
 In general, DMAs is the predominant arsenic species found in the urine of exposed 
humans, of which a significant portion is present as DMAsIII (159).  Furthermore, data 
presented in Chapter IV demonstrates the predominance of DMAs species in adipose tissue 
and skeletal muscle isolated from mice exposed to iAs for 8 weeks.  Our previous studies 
determined that DMAsIII, like iAsIII and MAsIII, inhibits ISGU by 3T3-L1 adipocytes at 
subtoxic concentrations that do not compromise cell viability.  The current studies confirm 
this finding and report that the mechanism responsible for the inhibition of ISGU by 
adipocytes exposed to DMAsIII is not dependent on the PDK-1/PKB/Akt signal transduction 
step, as it is for iAsIII and MAsIII.  Figure 3.4 illustrates the inability of DMAsIII to suppress 
the insulin-mediated phosphorylation of PKB/Akt on Ser473 and Thr308 while Figure 3.5 
demonstrates the failure constitutively active myr-PKB/Akt to prevent the inhibition of ISGU 
in adipocytes by DMAsIII.   
 Interestingly, DMAsIII suppressed insulin-mediated GLUT4 translocation to the 
plasma membrane, even though PKB/Akt phosphorylation was not suppressed.  These data 
suggest that DMAsIII inhibits ISGU by 3T3-L1 adipocytes via processes related to the 
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Figure 3.5:  Constitutive activation of PKB/Akt prevents the inhibition of insulin-
stimulated glucose uptake in adipocytes treated with subtoxic concentrations of iAsIII, 
MAsIII but not DMAsIII.  Basal and insulin-stimulated [14C]-2-deoxyglucose uptake by 
3T3-L1 adipocytes treated for 4 h with 50 μM iAsIII, 2 μM MAsIII, or 5 μM DMAsIII and 
by untreated adipocytes expressing a constitutively active myr-PKB/Akt (closed bar), an 
inactive A2myr-PKB/Akt (hatched bar), or an empty expression vector (open bar).  Each 
value represents the mean ± SD, n = 4-5. *Statistically significant differences (p<0.05) 
between treated and control cells.
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activation and/or mobilization of GLUT4 vesicles to the plasma membrane.  One prospective 
mechanism would involve the disruption of cytoskeletal components such as filamentous-
actin (F-actin) or tubulin.  The importance of cytoskeletal remodeling in GLUT4 
translocation has been demonstrated by the ability of chemical compounds, such as 
latrunculin B and jasplakinolide (which inhibit actin polymerization and remodeling), to 
diminish the presence of GLUT4 at the plasma membranes of insulin-stimulated 3T3-L1 
adipocytes and consequently inhibit ISGU (160).  Arsenite has been shown to bind to actin 
and tubulin in human lymphoblastoid cells (110) and to inhibit the synthesis of cytoskeletal 
proteins in Swiss 3T3 mouse cells (111).  Currently no data are available demonstrating the 
interaction of DMAsIII with cytoskeletal components in cells. 
 Further study of the mechanisms responsible for the inhibition of ISGU by adipocytes 
exposed to DMAsIII are of great interest, however, as discussed in the introduction to this 
chapter, the source of the experimental variation present in experiments related to the effects 
of DMAsIII must be identified and minimized before meaningful data can be attained.   
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CHAPTER IV 
EXAMINATION OF THE EFFECTS OF ARSENIC ON GLUCOSE HOMEOSTASIS IN 
CELL CULTURE AND ANIMAL STUDIES:  DEVELOPMENT OF A MOUSE MODEL 
FOR ARSENIC-INDUCED DIABETES 
David S. Paul, Araceli Hernández-Zavala, Felecia S. Walton, Blakely M. Adair, Jiří Dĕdina, 
Tomáš Matoušek, Miroslav Stýblo.  Toxicol. Appl. Pharm. 2007 (in press) 
4.1 Abstract 
 Previous epidemiologic studies found increased prevalences of type 2 diabetes 
mellitus in populations exposed to high levels of inorganic arsenic (iAs) in drinking water.  
Although results of epidemiologic studies in low-exposure areas or occupational settings 
have been inconclusive, laboratory research has shown that exposures to iAs can produce 
effects that are consistent with type 2 diabetes.  The current paper reviews the results of 
laboratory studies that examined the effects of iAs on glucose metabolism and describes new 
experiments in which the diabetogenic effects of iAs exposure were reproduced in a mouse 
model.  Here, weanling male C57BL/6 mice drank deionized water with or without the 
addition of arsenite (25 or 50 ppm arsenic) for 8 weeks.  Intraperitoneal glucose tolerance 
tests revealed impaired glucose tolerance in mice exposed to 50 ppm iAs, but not to 25 ppm 
iAs.  Exposure to 25 and 50 ppm iAs in drinking-water resulted in proportional increases in 
the concentration of iAs and its metabolites in the liver and in organs targeted by type 2 
diabetes, including pancreas, skeletal muscle and adipose tissue.  Dimethylarsenic was the 
predominant form of arsenic in the tissues of mice in both 25 and 50 ppm groups.  Notably, 
the average concentration of total speciated arsenic in livers from mice in the 50 ppm group 
was comparable to the highest concentration of total arsenic reported in the livers of 
Bangladeshi residents who had consumed water with an order of magnitude lower level of 
iAs.  These data suggest that mice are less susceptible than humans to the diabetogenic 
effects of chronic exposure to iAs due to a more efficient clearance of iAs or its metabolites 
from target tissues. 
 
4.2 Introduction 
Arsenic is a naturally occurring toxic metalloid found in the environment in both 
inorganic and organic forms. Inorganic arsenic (iAs) is the predominant form of arsenic in 
surface and underground water reservoirs.  Drinking-water containing high levels of iAs and 
industrial pollution are major sources of iAs exposure for millions of people throughout the 
world.  Countries where arsenic levels in drinking-water have been found to exceed the 
World Health Organization Standard of 10 μg/L include Argentina, Australia, Bangladesh, 
Chile, China, Hungary, India, Mexico, Peru, Taiwan, and the United States of America (161). 
Adverse health effects associated with chronic exposure to iAs have been documented in 
most of these countries.  It is estimated that more than 50 million people in Bangladesh (162) 
and 13 million residents of the U.S. (163) are exposed to drinking-water with iAs 
concentrations at or above 10 μg/L.  iAs is classified as a human carcinogen (71).  Numerous 
epidemiologic studies have associated chronic exposure to iAs with increased prevalence of 
cancers of the skin, bladder, liver, lung, and stomach (56-70).  Previous research of the 
effects of chronic exposure to iAs has focused primarily on its carcinogenic potential. 
However, chronic exposures to iAs from the environment or in occupational settings have 
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also been linked to non-carcinogenic diseases, including peripheral vascular disease, 
cardiovascular and cerebrovascular diseases (74-80), hypertension (74), goiter (81), 
hepatomegaly (82), respiratory system dysfunction (83), nervous system dysfunction (84-86), 
and diabetes mellitus (87-90).  
 
4.2.1 Epidemiologic Evidence of the Association between Chronic Exposure to iAs and 
Diabetes Mellitus 
Studies examining the role of iAs exposure on the development of diabetes represent 
a growing area of research.  Diabetes refers to a group of metabolic diseases characterized by 
systemic disruption of glucose homeostasis.  Insulin-dependent (type 1) diabetes is caused by 
the autoimmune destruction of insulin-producing pancreatic β-cells, resulting in a severe 
deficiency of circulating insulin (hypoinsulinemia) and the concomitant elevation of blood 
glucose (hyperglycemia).  Non-insulin-dependent (type 2) diabetes is characterized by 
hyperglycemia due to the resistance of peripheral tissues such as adipose tissue, skeletal 
muscle and the liver to insulin stimulus and consequently the increased production of insulin 
by pancreatic β-cells.  Gestational diabetes (type 3) is similar to type 2 diabetes with respect 
to its pathogenesis and clinical symptoms; however, it occurs in women during pregnancy 
and usually improves or disappears after child birth.  The pathogenesis of arsenic-induced 
diabetes is unknown.  Diagnosis of diabetes in populations exposed to iAs has relied 
primarily on measurements of fasting blood glucose, glucosuria, glycosylated hemoglobin 
(HbA1c), oral glucose tolerance tests, clinical history of the disease or mortality linked to 
diabetes.  The results of these diagnoses are suggestive of insulin resistance and type 2 
diabetes; however, β-cell dysfunction cannot be ruled out.   
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The association between iAs exposure via drinking-water and increased risk of 
developing type 2 diabetes was first reported in Taiwan by Lai and associates (87).  These 
authors found a twofold increase in the prevalence of diabetes mellitus among residents of 
arseniasis-endemic areas as compared to residents in non-endemic areas.  Furthermore, a 
significant dose-response relationship was found between cumulative exposure to iAs and the 
prevalence of diabetes.  The link between diabetes mellitus and consumption of water 
containing iAs was later confirmed by several cross-sectional and cohort studies from 
Taiwan (88) and Bangladesh (89,90).  Other studies have examined the association between 
exposure to iAs in occupational settings and the occurrence of symptoms that are consistent 
with diabetes (92-94). These studies were retrospective in nature and primarily used death 
certificates as their diagnostic criteria. It should be noted that some of the epidemiologic 
studies linking chronic exposures to iAs with type 2 diabetes suffer serious problems 
associated mainly with insufficient assessment of exposure to iAs, inadequate diagnosis of 
diabetes or lack of dose-response data. A critical review of these studies has recently been 
published by Navas-Acien and associates (95). These authors concluded that methodological 
problems limit the causal interpretation of the moderately strong association between iAs 
exposure and diabetes in Taiwan and Bangladesh. Overall, the epidemiologic evidence was 
regarded as insufficient and inadequate to establish causality. 
 
4.2.2 Laboratory Studies of the Effects of arsenic on Glucose Metabolism 
The effects of arsenic on glucose metabolism have been examined by numerous 
laboratory studies. However, it should be noted that arsenic has traditionally been used, along 
with other chemical or physical agents, as an acute stressor in research of stress-mediated cell 
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signaling or stress-induced responses in various metabolic pathways, including the pathways 
of carbohydrate metabolism.  Studies in this area of research have examined insulin secretion 
and glucose metabolism in cultured cells or laboratory animals exposed to highly toxic 
concentrations of arsenic, which are incompatible with chronic exposures in humans.  
Therefore, data from these studies cannot be evaluated with respect to possible mechanisms 
of diabetes induced by environmental or occupational exposures and attempts to do so would 
inevitably yield confusing results (95). The following is a brief contextual review of 
laboratory studies that have examined the effects of arsenic on processes directly related to 
glucose homeostasis. 
 
4.2.2.1 Effects on glucose uptake 
Insulin-stimulated glucose uptake (ISGU) by skeletal muscle and adipose tissue is a 
key process responsible for the normalization of postprandial blood glucose levels.  Results 
of early laboratory studies suggest that disruption of ISGU is a potential mechanism 
responsible for the development of type 2 diabetes in response to chronic exposures to iAs.  
In 1985, Frost and associates reported that phenylarsine oxide (PAO), a aromatic derivative 
of trivalent arsenic (AsIII), is a potent inhibitor (Ki = 7 μM) of ISGU by murine 3T3-L1 
adipocytes (129). Micromolar concentrations of PAO have also been reported to inhibit 
ISGU by isolated rat skeletal muscle (126,164).  Later reports have shown that the inhibition 
of ISGU in 3T3-L1 adipocytes treated with PAO is associated with hypophosphorylation of 
two endogenous phosphoproteins (p24 and p240), possible components of the insulin-
stimulated signal transduction pathway (129).  Notably, PAO does not interfere with the 
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insulin-dependent phosphorylation of the insulin receptor or interact directly with glucose 
transporters (128,129).   
The effects of PAO and other arsenicals on basal (insulin independent) glucose 
uptake have also been examined by several studies that focused mostly on stress-induced 
responses in cultured cells. These studies used high concentrations of arsenicals that are 
cytotoxic for most cell types. Here, PAO (50 μM) or iAsIII (200-1000 μM) have been shown 
to stimulate basal glucose uptake in baby hamster kidney (BHK) cells (116,118,119,165), 
bovine chromaffin cells (166), 3T3-L1 adipocytes (112,113,167) and in L6 myotubes (168).  
A modest 1-3 fold increase in basal glucose uptake was typically found with no effect on the 
translocation of GLUT4, an insulin-sensitive glucose transporter, to the plasma membrane. 
Only one study showed an increased presence of GLUT4 at the plasma membrane of BHK 
cells in response to treatment with PAO (35 μM) (119).  In contrast, two studies reported 
inhibition of basal glucose uptake in Madin-Darby canine kidney (MDCK) cells treated with 
25 μM PAO or 1000 μM iAsIII (125) and in rat tubule kidney (RTK) cells treated with 2 μM 
PAO (169).  The increase in basal glucose uptake by toxic concentrations of PAO or iAsIII 
was associated with the activation of a stress response, p38 MAPK-mediated signal 
transduction pathway in several studies (112,113,166).  Phosphorylation of p38 MAPK has 
been shown to increase intrinsic activity of GLUT4 transporters already present at the plasma 
membrane, resulting in increased glucose uptake by cells (170,171).  In several studies, toxic 
concentrations of iAsIII were used explicitly for their capacity to activate the p38 MAPK 
pathway and to induce acute stress. 
Data from previous studies indicate that an alternative mechanism for increased basal 
glucose uptake by cells exposed to high concentrations of trivalent arsenicals may involve 
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the activation of phosphatidylinositol-3-kinase (PI-3K) and PI-3K-dependent 
phosphorylation of protein kinase B (PKB/Akt). Increased PI-3K-mediated PKB/Akt 
phosphorylation has been reported in cells exposed to toxic concentrations (200-500 μM) of 
iAsIII (143,168).  Stress-induced phosphorylation of PKB/Akt is associated with the 
activation of pro-survival mechanisms aimed at preventing apoptosis and promoting cell 
proliferation (172-174).  However, PKB/Akt phosphorylation is also one of the key steps in 
the activation of GLUT4 transporters by insulin (106,130).  Thus, exposure to toxic 
concentrations of trivalent arsenicals may mimic the action of insulin by activating the p-
PKB/Akt-mediated glucose transport in cells expressing GLUT4. 
Taken together, studies examining glucose transport in cell culture systems suggest 
that acute stress induced by exposures to toxic concentrations of trivalent arsenicals is 
associated with p38- or p-PKB/Akt-mediated increase in basal, insulin-independent, glucose 
uptake. In contrast, exposures to low micromolar concentrations of PAO inhibit ISGU. It 
should be noted that PAO is not a metabolite of iAs and its chemical properties and 
metabolic fates differ from those of iAs or its methylated metabolites.  Therefore, while 
studies using subtoxic concentrations of PAO may provide valuable insights into the 
diabetogenic effects of chronic exposures to iAs, the significance of these studies for 
evaluation of the molecular mechanisms underlying effects of iAs or its metabolites is 
limited. 
The effects of physiologically relevant trivalent arsenicals, the known metabolites of 
iAs, on ISGU and insulin-activated signal transduction have been examined in this 
laboratory.  Here, dose-dependent decreases in ISGU were observed in 3T3-L1 adipocytes 
exposed for 4 or 24 h to subtoxic concentrations of iAsIII, or the methylated metabolites of 
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iAs, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII) (32).  We have recently shown 
that two of these arsenicals, iAsIII or MAsIII, inhibit the activity of 3-phosphoinositide 
dependent kinase 1 (PDK-1) and the subsequent PDK-1-catalyzed phosphorylation of 
PKB/Akt (175).  Notably, DMAsIII inhibited GLUT4 translocation in insulin-activated 
adipocytes by a mechanism independent of PKB/Akt phosphorylation.  Results from other 
laboratories suggest that metabolites of iAs may also interfere with glucose metabolism by 
inhibiting α-ketoglutarate dehydrogenase or pyruvate dehydrogenase (132,176), two rate 
limiting enzymes involved in the oxidative metabolism of carbohydrates.  However, it is 
unclear whether concentrations of iAs metabolites in tissues of chronically exposed 
individuals can reach levels necessary for inhibition of these enzymes.  
 
4.2.2.2 Effects on β-cell function 
Compared with data on glucose metabolism and insulin signaling in mammalian cells 
exposed to trivalent arsenicals, much less information is available on the effects of arsenicals 
on insulin production by β-cells.  Insulin is a metabolic hormone produced and secreted by β-
cells in response to elevated blood glucose concentrations and is responsible for the 
stimulation of glucose uptake by peripheral adipose and skeletal muscle tissues as well as the 
suppression of gluconeogenesis in the liver.  Insulin insufficiency has deleterious effects on 
glucose homeostasis and contributes to the pathogenesis of type 1 and type 2 diabetes.  
Several studies have examined the effects of arsenicals on pancreatic/duodenal homeobox-1 
(PDX-1, also identified as insulin upstream factor 1), a transcription factor that binds to the 
promoter of the preproinsulin gene in response to elevated blood glucose concentrations.  
PDX-1 DNA binding was found to be increased in isolated human islets and MIN6 cells, a 
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mouse β-cell line, treated with iAsIII for 30 min (177).  In addition, iAsIII was found to 
promote PDX-1 activation and translocation to the nucleus, which is a critical step in the 
stimulation of preproinsulin mRNA transcription (178,179).  However, both these studies 
used a toxic (1 mM) concentration of iAsIII to induce stress-activated p38 MAPK, which is 
believed to play a role in regulating insulin production in response to glucose stimulus.  In 
contrast with the stimulatory effects of millimolar iAsIII, toxic (5 mM) concentration of a 
pentavalent iAs, arsenate (iAsV), has been shown to disrupt insulin secretion by interfering 
with pancreatic islet respiration (180).  Because of the acute nature of the exposure, the 
significance of these findings for chronic environmental exposures is questionable.  The 
effects of low micromolar concentrations of iAsIII on β-cell function have recently been 
examined (181).  The authors reported that exposures to a subtoxic (5 μM) concentration of 
iAsIII for 72 h inhibits glucose-stimulated expression of preproinsulin and insulin secretion by 
isolated rat pancreatic islets.  These data indicate that inhibition of insulin production by 
pancreatic β-cells may play an important role in the development of impaired glucose 
tolerance in individuals exposed to iAs. 
 
4.2.3 Laboratory Studies in Animals 
 The potential mechanisms responsible for the diabetogenic effects associated with 
chronic exposures to iAs provided by in vitro studies have not yet been validated by in vivo 
experiments.  Previous in vivo studies have examined blood glucose or insulin levels in goats, 
rats, or mice after exposures to iAsV or iAsIII via food, drinking water or intraperitoneal 
injection (120-123,182-185).  The dose, duration and form of arsenic used in these studies 
have varied greatly, producing conflicting results and confusing the interpretation of data 
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with respect to environmental exposures to iAs in humans. The effects of iAs exposure on 
glucose tolerance in mice have recently been examined in this laboratory. The experimental 
section of this report describes the development of a mouse model for diabetes induced by 
chronic exposure to iAs in drinking water. The diabetogenic effects of iAs exposure are 
evaluated with respect to tissue retention and distribution of iAs metabolites.  
 
4.3 Materials and methods 
4.3.1 Chemicals 
 Sodium arsenite (99% pure) was purchased from Sigma-Aldrich (St. Louis, MO). 
Sodium borohydride (NaBH4) was from EM Science (Gibbstown, NJ). Ultrapure phosphoric 
acid was obtained from J.T. Baker (Phillipsburg, NJ). Sodium arsenate (96%, Sigma), 
monomethylarsonate (MAsV), disodium salt (98%, Chem Service, West Chester, PA), 
dimethylarsinic acid (DMAsV) (98%, Strem Chemicals, Inc., Newburyport, MA) and 
trimethylarsine oxide (TMAsVO, gift from Dr. William Cullen, UBC, Vancouver) were used 
as standards for speciation analysis of arsenic in mouse tissues.  All other chemicals used 
were the highest grade commercially available. 
 
4.3.2 Animals 
 Four-week-old male weanling C57BL/6 mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME, USA) and housed five per cage with free access to food and 
drinking water (see below).  All mice were housed in polycarbonate cages with corn cob 
bedding in the University of North Carolina Animal Facility (12 h light/dark cycle, 22 ± 1°C 
and humidity of 50 ± 10%), which is fully accredited by the American Association for 
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Accreditation of Laboratory Animal Care. Animals were allowed free access to food (Lab 
Diet 5058, Nutrition International, Brentwood, MO) and deionized water (dH2O). Mice in 
two groups (5 animals each) drank dH2O with the addition of iAsIII (25 or 50 ppm iAs).  The 
third group (n = 5) drank pure dH2O. Water containing iAsIII was freshly prepared every 3-4 
days to minimize oxidation to iAsV.  Water consumption and body weights were monitored 
in all exposure groups every week or two weeks, respectively.  
 
4.3.3 Intraperitoneal Glucose Tolerance Test 
 Mice were fasted 5 h prior to administration of the IPGTT. D-glucose (Sigma) was 
dissolved in phosphate buffered saline and administered to mice via i.p. injection (2 g/kg).  
Samples of whole-blood (2-3 μl each) were collected from a tail clip bleed immediately 
before and 15, 30, 60, 90, and 120 min after glucose injection. Blood glucose levels were 
measured using a Freestyle Glucose Monitoring System (Abbott Laboratories, Abbott Park, 
IL.) 
 
4.3.4 Speciation Analysis of Arsenic 
 Freshly dissected tissues were aliquoted into 2.0 ml cryotubes, snap frozen in liquid 
nitrogen and stored at -70o C until analysis. Speciated arsenicals in tissues were determined 
by automated hydride generation-atomic absorption spectrometry (HG-AAS) coupled with a 
cryotrap. Tissues were digested overnight in 2 M ultrapure phosphoric acid (90°C) (186).  
The digestion converts all trivalent arsenicals to pentavalency.  Phosphoric acid in digested 
samples was neutralized by NaOH.  L-cysteine was added to each sample at a final 
concentration of 2%.  For analysis of TMAsVO, samples were analyzed without cysteine 
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(134).  Arsines were generated from a 500 μl aliquot of the digested tissue, which was 
injected into a flow of deionized water continuously mixed with a flow of 0.75M TRIS-HCl 
buffer (pH 6) and a flow of 1% NaBH4 in 0.1% NaOH/ 0.02% antifoam B silicone emulsion, 
all at the rate of 1 ml/min. Arsines were cryotrapped and separated by boiling points, as 
previously described (134).  The content of arsenic in arsines was determined using a Perkin-
Elmer model 5100 atomic absorption spectrometer equipped with a quartz multiatomizer 
(187). Under these conditions, this method routinely resolves arsines generated from iAsV, 
MAsV, DMAsV, and TMAsVO. Five concentrations (0.05, 0.25, 0.5, 1 and 2.5 ng/ml) of each 
of these arsenicals were used to prepare calibration curves. Arsenicals in tissue samples were 
identified by spiking with appropriate arsenic standards at several concentrations. The 
concentration of total speciated arsenic for each tissue sample was calculated as the sum of 
concentrations of iAsV, MAsV, DMAsV, and TMAsVO. In order to determine the recovery of 
arsenic during the HG-AAS analysis, the total arsenic in selected tissues was analyzed by 
graphite furnace (GF) AAS using a Perkin-Elmer model 5100 atomic absorption 
spectrometer with an autosampler. For this analysis, tissues were microwave digested (CEM, 
Model MARS 5) following the 3052 EPA method with some modifications. Briefly, 0.1 g of 
tissue was completely digested in 70% nitric acid in a total volume of 10 ml. A 1-ml aliquot 
of each digestate was diluted with 20% nitric acid to a final volume of 5 ml.  A 40 μl aliquot 
of this solution was injected into the GF along with 10 μl of a chemical modifier (5 μg of 
palladium and 5 μg of magnesium nitrate in 2% nitric acid). The GF program included a 
drying step at 130˚ C for 40s, ashing step at 1300˚ C for 40s, and atomization step at 2300˚ C 
for 3s. The recovery of arsenic was calculated as the total speciated arsenic concentration 
(determined by HG-AAS) divided by the total arsenic concentration (determined by GF-
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AAS) for each tissue. HG-AAS was also used for analysis of arsenic species in all lots of the 
laboratory diet used in this study. 
 
4.4 Results 
Water Consumption and Body Weights 
 Water consumption by mice in each exposure group was measured twice a week 
throughout the course of the study. An initial decline in water intake, possibly indicative of 
an acclimation period, was noted for all groups (Fig 4.1A).  However, water consumption 
stabilized by week 2 for the 25 ppm and 50 ppm groups, and by week 3 for the control group. 
Control mice consumed an average of 5.0 ml of water per day (ml/d).  Mice in the 25 ppm 
and 50 ppm group consumed significantly less water: 3.8 ml and 2.5 ml per day, respectively 
(Fig 4.1B). Average daily arsenic intake in drinking water per mouse was estimated based on 
the water consumption.  Mice in the 25 ppm group ingested 94.7 μg of arsenic/day via 
drinking water while mice in the 50 ppm group ingested 125.3 μg of arsenic/day (Fig 4.1C).  
The laboratory diet was a minor source of arsenic. The total arsenic concentration in several 
lots of the diet ranged from 19.5 to 28.6 ng/g.  Notably, iAs was the main arsenic species, 
accounting for 70 to 80% of the total arsenic in the diet.  Body weights of mice in each group 
were measured prior to exposure and every two weeks thereafter until the conclusion of the 
study (Fig 4.2A).  Although weight gains were not significantly different between groups at 8 
weeks, mice in the 50 ppm group appeared to stop gaining weight between weeks 4 and 6.  
However, this trend did not reach statistical significance.  Mice in the control group gained in 
average 7.3 g through week 8 (Fig 4.2B) as compared to 7.5 g and 5.3 g for mice in the 25 
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Figure 4.1:  Water consumption by mice in the treatment groups: (A) Changes in the daily 
water consumption by mice exposed to 25 ppm arsenic (•) and 50 ppm arsenic () and by
control mice ().  (B) The average daily consumption of water by mice in the control, 25 
ppm, and 50 ppm groups.  (C) Estimated average intake of arsenic by mice in the 25 ppm 
and 50 ppm groups. (Mean and SD, n = 5.) *Value is significantly different (P < 0.05) from 
that in the control group. 
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Figure 4.2:  Body weights of mice in the treatment groups: (A) Changes in the body 
weights of mice exposed to 25 ppm arsenic (•) and 50 ppm arsenic () and control 
mice () (Mean ± SD, n = 5). (B) The average body weights of mice in the control, 
25 ppm, and 50 ppm groups at the beginning () and the end () of the study. (Mean 
and SD, n = 5.) 
 
 
74
ppm and 50 ppm groups, respectively (Fig 4.2B).  Additionally, no significant differences 
were noted in liver weights between experimental groups (data not shown).  No obvious 
signs of pathology were noted in dissected tissues. 
 
Effect of iAs exposure on glucose tolerance 
 To determine the effects of iAsIII ingestion on glucose tolerance, mice in all exposure 
groups were subjected to IPGTT (Fig 4.3).  No significant differences in fasting blood 
glucose concentrations were noted prior to glucose administration.  All groups exhibited the 
characteristic rapid rise in blood glucose within 15-30 min of glucose challenge, followed by 
a gradual decrease in blood glucose concentrations that began 30 min after injection and 
approached baseline levels by 120 min.  The 50 ppm group experienced the greatest increase 
in blood glucose concentration, reaching 24.6 mmol/L 15 min post injection, which was 
significantly higher than the peak blood glucose concentration of 16.9 mmol/L in the control 
group.  Blood glucose levels in the 50 ppm group remained significantly higher than those of 
control mice at 30 and 60 min after injection.  No significant differences were noted between 
control and 50 ppm groups at 90 and 120 min post injection or between control and 25 ppm 
groups anytime during the IPGTT. 
 
Concentrations of arsenic species in mouse tissues 
 Traces of arsenicals were detected in tissues of control mice that were exposed only 
to arsenic from the diet.  The concentrations of total speciated arsenic in adipose tissue, 
pancreas, skeletal muscle, and liver increased proportionally with the intake of iAs from 
drinking water (Fig 4.4).  The concentrations of total speciated arsenic were 1.8- to 3.7-fold 
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Figure 4.3:  Glucose concentrations in the blood of mice before and during the 
intraperitoneal glucose tolerance test: Mice exposed to 25 ppm arsenic (•) and 50 ppm
arsenic () for 8 weeks and control mice (). (Mean ± SD, n = 5.) *Value is 
significantly different (P < 0.05) from that in the control group.  
Figure 4.4:  Dose-dependent increases in the total speciated arsenic (iAsV + MAsV + 
DMAsV) levels in adipose tissue (+), pancreas (), skeletal muscle (●), and liver (▲) of 
mice exposed to 25 ppm and 50 ppm arsenic for 8 weeks. (Mean ± SD, n = 5.) 
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Figure 4.5:  Arsenic species in adipose tissue, skeletal muscle, pancreas, and livers of 
control mice (A) and mice exposed to 25 ppm (B) and 50 ppm arsenic for 8 weeks (C): 
iAsV (solid black), MAsV (solid white) and DMAsV (hatched). (Mean; n = 5 for adipose 
tissue, skeletal muscle, and liver; n = 3 for pancreas.) 
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higher in tissues of mice in the 50 ppm group as compared to mice in the 25 ppm group. For 
both groups, the highest concentrations of total speciated arsenic were found in the liver and 
the lowest in adipose tissue.  The results of arsenic speciation in tissues from mice in all three 
experimental groups are shown in Figure 4.5.  Notably, tissues of control mice contained 
almost exclusively iAs (Fig 4.5A).  In this group of mice, the highest levels of iAsV were 
found in adipose tissue, followed by skeletal muscle, liver and pancreas.  In contrast, tissues 
of mice from the 25 ppm (Fig 4.5B) and 50 ppm groups (Fig 4.5C) contained iAsV, MAsV 
and DMAsV. TMAsVO was not detected in tissues of mice in either the 25 or 50 ppm groups.  
DMAsV was the predominant arsenic species in all tissues collected from mice in these 
groups.  However, in the liver a significant fraction of arsenic was represented by iAsV: 39.8 
and 29.4% for the 25 and 50 ppm groups, respectively. To examine the recovery of arsenic 
during the HG-AAS analysis, total arsenic content was determined in livers and skeletal 
muscle from mice in the 50 ppm group, using GF-AAS.  Based on the comparison of the 
HG-AAS and GF-AAS data, the average recovery of arsenic was 110% for skeletal muscle 
and 105% for the liver.  Because of limited access to GF-AAS, total arsenic concentration 
was not measured in pancreas or adipose tissue.  
 
4.5 Discussion 
 Impaired glucose tolerance, an early indicator of insulin resistance and diabetes 
mellitus, signifies the inability of peripheral tissues to perform glucose uptake at rates that 
are sufficient to prevent excessive post-prandial blood glucose elevations.  Previous reports 
on the effects of arsenic exposure on glucose homeostasis and in vivo insulin and 
carbohydrate metabolism in laboratory animals have been inconsistent due in part to 
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variations in choice of animal species (mice, rats, goats) and arsenicals (iAsIII, iAsV, MAsIII, 
and MAsV), as well as the route (i.p. vs. p.o.), concentration (0.025 ppm – 1,300 ppm), and 
duration (7 days – 2 years) of exposure.   The present study introduces a viable mouse model 
to investigate in vivo diabetogenic effects of chronic exposures to iAs in drinking-water.  We 
chose the C57BL/6 mouse strain for this study because of its low baseline occurrence of type 
2 diabetes but high susceptibility to the development of diet-induced type 2 diabetes (188-
190).  Our results show that 8 week exposure of C57BL/6 mice to 50 ppm iAsIII in drinking-
water promotes impaired glucose tolerance, which is consistent with diabetes mellitus.  
However, the concentration of iAs in drinking water needed to produce this effect is an order 
of magnitude higher than iAs concentrations shown to produce arseniasis symptoms, 
including diabetes, in humans.  For example, in arseniasis-endemic areas of Bangladesh, the 
concentration of iAs in drinking water can reach 3.4 ppm (191). Liver samples from local 
residents who developed hepatomegaly as a result of drinking water with 0.22 to 2 ppm iAs 
contained from 500 to 6,000 μg of arsenic/kg dry weight (192).  This corresponds to 
approximately 100 to 1,200 μg of arsenic/kg of intact liver.  In our studies, similar 
concentrations of total speciated arsenic were found in livers of mice drinking water with 25 
and 50 ppm iAsIII: 423 and 1,165 μg of arsenic/kg, respectively.  Results of an independent 
study carried out in this laboratory showed that livers of mice exposed to 1 or 10 ppm iAsIII 
in drinking water for 8 weeks contained on average only 11 and 155 μg of arsenic/kg, 
respectively (Paul, D.S., unpublished data).  These data suggest that mice metabolize iAs and 
clear iAs metabolites from tissues more efficiently than humans and that significantly higher 
exposure levels or longer exposure times are needed in mice to produce symptoms of chronic 
arsenic toxicity found in humans.   
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 It should be noted that the concentrations of iAs metabolites in tissues of mice in the 
25 ppm and 50 ppm groups (Fig. 4.5B,C) were not in proportion with the corresponding 
estimated intakes of iAs from drinking water (Fig. 4.1C). The tissue concentrations of iAs 
metabolites in the 50 ppm group were several fold greater than in the 25 ppm group, despite a 
relatively small difference in iAs intake. This may be, in part, due to significantly lower 
water consumption by mice in the 50 ppm as compared to the 25 ppm group. (Fig. 4.1A,B). 
The smaller amount of water consumed daily by mice in the 50 ppm group would result in a 
decreased urine production and possibly, in a less efficient excretion of iAs metabolites in the 
urinary tract. Thus, the profound increase in tissue retention of iAs metabolites in the 50 ppm 
as compared to the 25 ppm group may be a combined effect of the increased iAs intake and 
the impaired clearance of iAs metabolites due to lower water consumption. The 
disproportional increase in the tissue concentrations of iAs metabolites in the 50 ppm group 
may explain why mice in this group developed impaired glucose tolerance while mice in the 
25 ppm group exhibited a normal pattern of glucose utilization.  
 As shown in Figure 4.1, mice in both 25 and 50 ppm groups consumed significantly 
less water than did control mice.  Although mice are generally resistant to prolonged 
dehydration (193), it is unclear if the decreased water intake could directly contribute to the 
impaired glucose tolerance in mice exposed to 50 ppm iAs.  The potential role of dehydration 
in modulating glucose metabolism and insulin sensitivity has been the subject of several 
studies.  In vitro studies have suggested that dehydration on the cellular level may disrupt 
insulin signaling and glucose metabolism via mechanisms related to cell volume (194,195). 
However, a recent study suggests that dehydration does not significantly impair insulin 
sensitivity or glucose metabolism in human subjects (196).  With no clear consensus 
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regarding the effects of dehydration on glucose tolerance, future studies should address this 
potential confounding factor when examining the effects of chronic exposures to iAs or other 
arsenicals in drinking water. 
 Although the present study shows that mice exposed to iAs in drinking water develop 
impaired glucose tolerance, the mechanisms underlying this outcome remain unclear.  We 
have previously shown that trivalent arsenicals, the metabolites of iAs, are potent inhibitors 
of insulin-stimulated glucose uptake in cultured adipocytes (32,175).  Subtoxic 
concentrations of iAsIII and MAsIII inhibited the insulin-dependent phosphorylation of 
PKB/Akt by PDK-1 and p-PKB/Akt-dependent translocation of GLUT4 to the plasma 
membrane.  In contrast, DMAsIII inhibited GLUT4 translocation by a PKB/Akt-independent 
mechanism.  Thus, it is plausible that the same mechanisms are responsible for impaired 
glucose tolerance in mice exposed to iAs in drinking water.  However, inhibition of insulin 
production in pancreatic β-cells by iAs or its metabolites may contribute to the overall 
diabetogenic effects of iAs exposure.  Future laboratory studies will clarify whether the 
impaired glucose tolerance results from the inhibition of insulin signaling and/or decreased 
insulin production by β-cells in this mouse model. Evaluation of these mechanisms with 
respect to tissue concentrations and the level of exposure to iAs and its metabolites will help 
to improve designs for future epidemiologic studies examining the association between the 
exposure to iAs in drinking water, the individual pattern of iAs metabolism, and the risk of 
developing diabetes mellitus.  
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CHAPTER V 
SYNTHESIS 
 
5.1 Introduction 
 This dissertation describes in vitro and in vivo studies that examined the effects of 
arsenic on glucose homeostasis.  The data provide evidence supporting the hypothesis that 
iAs and its metabolites interfere with insulin signaling and glucose metabolism in exposed 
human populations.  We demonstrate a mechanistic basis for the impairment of ISGU in 
adipocyte cell cultures exposed to subtoxic concentrations of iAsIII and its methylated 
metabolites, MAsIII and DMAsIII.  We also report the development of an in vivo model for 
studying the effects of chronic iAs-exposure on glucose metabolism and homeostasis.  This 
chapter summarizes the results of these projects and discusses the implications of the data. 
 
5.2 Summary and Implications of In Vitro Studies  
 Decreased ISGU by peripheral tissues, such as adipose tissue and skeletal muscle, is a 
hallmark of type 2 diabetes and therefore represents a potential mechanism by which arsenic 
may promote the development of diabetes in chronically exposed populations.  
Unfortunately, the current literature regarding the effects of arsenic on glucose uptake and 
metabolism has been confounded by reports which have examined the effects of high 
concentrations of synthetic arsenicals on cell types that do not play a significant role in 
glucose metabolism.  Most of these reports have also failed to characterize the toxicities of 
arsenic-containing compounds used in studies of glucose uptake and metabolism.  Our in 
vitro studies represent a novel approach because they are, to the best of our knowledge, the 
first and only systematic examination of the effects of physiologically relevant arsenicals 
(metabolites of iAs) on ISGU by cultured adipocytes, a cell type that plays a critical role in 
glucose metabolism and whole body glucose homeostasis.  Importantly, our investigations 
demonstrate that inhibition of ISGU by adipocytes exposed to subtoxic concentrations of 
iAsIII and MAsIII is the result of inhibition of PDK-1 catalyzed phosphorylation of PKB/Akt.  
We also determined that subtoxic concentrations of DMAsIII inhibit ISGU independently of 
the insulin-mediated PDK-1/PKB/Akt signal transduction step.  The different mechanisms 
responsible for the diabetogenic effects of iAsIII and MAsIII versus DMAsIII support the 
theory that, biomethylation of ingested iAs is an important factor in determining the extent 
and character of arsenic-related health effects.  
 Our in vitro studies contribute towards understanding the effects of arsenic on ISGU.  
Furthermore, these experiments provide a mechanistic basis for the development of arsenic-
induced diabetes in chronically exposed human populations. 
 
5.3 Summary and Implications of In Vivo Studies 
 Our attempt to establish an in vivo mouse model for arsenic-induced diabetes 
represents an important first step toward the systematic characterization of the effects of 
chronic iAs-exposure on glucose metabolism.  Our in vivo studies are novel because they are 
the first to demonstrate the impairment of glucose tolerance in C57BL/6 mice that are 
exposed to iAsIII in drinking-water.  Previously published studies have failed to generate 
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diabetic-like symptoms (e.g. impaired glucose tolerance, elevated fasting blood glucose and 
insulin, elevated levels of glycosylated hemoglobin, HbA1c) in mice exposed to arsenic at 
levels that are consistent with those experienced by human populations.  Critics may argue 
that we exposed mice to iAsIII in drinking-water at levels that are excessive when compared 
to what is seen in human populations, however the amount of arsenic retained in livers of our 
exposed mice is strikingly similar to the amount of arsenic retained in the livers of human 
subjects exposed to drinking-water containing less than 2 ppm of arsenic.  We attribute this 
concordance in arsenic tissue concentrations to the relatively high capacity of mice to clear 
and excrete arsenic in the urine or hair as compared to humans.  The ability of mice to 
methylate and clear arsenic from target tissues more efficiently than humans may be the 
determining factor that endows mice with a relative resistance to the development of arsenic-
induced diseases.  Our data highlight the need for researchers to carefully consider the dosing 
of mice with arsenic when attempting to model the arsenic-related health effects observed in 
humans and to evaluate the exposure levels and effects with respect to the concentration and 
speciation of arsenicals in target tissues.  Our efforts provide the scientific community with 
convenient mouse model for future research examining the effects of iAs on glucose 
metabolism and arsenic-induced diabetes. 
 
5.4 Future Studies 
 Future in vitro studies should identify the molecular target(s) of DMAsIII that are 
responsible for the inhibition of ISGU in adipocytes exposed to this arsenical as well as 
examine the effects of iAsIII, MAsIII and DMAsIII on other tissues involved in glucose 
clearance and homeostasis, namely skeletal muscle, liver, and pancreas.   
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 Cultured adipocytes are a convenient and reliable model for studying ISGU; however 
they are not an adequate substitute for skeletal muscle, the chief organ responsible for 
glucose disposal and storage in humans.  Skeletal muscle cell culture models, such as C2C12 
and L6 myotubes, contain significantly more protein and less stored lipid than adipocytes.  In 
addition, myotubes express other GLUT transporters, such as GLUT1 and GLUT3 (197,198), 
which may play a role in arsenic uptake and efflux.  Our analysis of tissue arsenic content in 
iAs-exposed mice revealed that significantly more arsenic was retained by skeletal muscle as 
compared to adipose tissue.  We hypothesize that myotubes exposed to iAs and its 
metabolites will exhibit decreased ISGU and provide further evidence for arsenic-induced 
impairment of glucose tolerance in exposed humans and mice.     
 The failure of the pancreas to produce or secrete insulin is associated with a profound 
disruption of glucose homeostasis and is typically observed in individuals with type 1 
diabetes and advanced type 2 diabetes.  Recent studies have reported the impairment of 
pancreatic function by arsenite (181), however a systematic evaluation of the effects of 
physiologically relevant arsenicals on the pancreatic tissues is currently lacking.  Future in 
vitro experiments could address this gap in the literature and deduce the potential 
mechanisms responsible by examining the effects of subtoxic concentrations of iAsIII or its 
metabolites on insulin production and secretion in model cell lines such as the MIN-6 or 
INS-1 insulinoma cells.     
 Our in vivo studies demonstrated that the livers of iAs-exposed mice retained the 
greatest amount of arsenic when compared to all other tissues analyzed.  The liver plays an 
important role in glucose homeostasis due to its status as the second largest glycogen storing 
organ after skeletal muscle, and the chief producer of glucose via gluconeogenesis.  Insulin 
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suppresses hepatic gluconeogenesis through a signaling pathway similar to that investigated 
in our in vitro studies of adipocytes.  The high level of arsenic retained by the liver and the 
important dual role this organ plays in arsenic methylation and glucose metabolism make 
future in vitro studies of the effects of arsenic on hepatic glucose metabolism of great 
interest.  These in vitro studies could be performed in HepG2 human hepatoma cells, as well 
as primary mouse or human hepatocytes.  
 Our data demonstrated the impairment of glucose tolerance in mice chronically 
exposed to iAs in drinking-water.  However our ability to draw conclusions regarding the 
mechanism(s) responsible for this impairment is limited by the lack of data on blood insulin 
concentrations during the IPGTT.  Elevated blood insulin levels in iAs-exposed mice in 
comparison to control mice would have been indicative of insulin resistance of peripheral 
tissues and possibly type 2 diabetes, while a relative deficiency in blood insulin levels in iAs-
exposed mice would have suggested a dysfunction of pancreatic β-cells characteristic of type 
1 diabetes.  Future studies will determine blood insulin concentrations under fasting 
conditions and during the IPGTT to better characterize the etiology of the observed 
impairment of glucose tolerance in iAs-exposed mice.  In addition, a determination of insulin 
sensitivity of peripheral tissues could be ascertained by performing an insulin tolerance test, 
in which fasted mice are injected with insulin and blood glucose is measured at ~15 minute 
intervals for 2-3 hours after insulin injection.     
 Clearly, the in vivo studies presented in this dissertation demonstrate the impairment 
of glucose tolerance in iAs-exposed mice; however, the mechanisms responsible for this 
impairment were not conclusively identified.  Our in vitro studies suggest that determination 
of ISGU capacity and the activities of enzymes such as PDK-1 and PKB/Akt in adipose 
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tissue and skeletal muscle obtained from tissues of iAs-exposed mice may be useful in 
elucidating the molecular mechanisms that contribute to the impairment of glucose tolerance 
observed in iAs-exposed mice.    
 Since a significant decrease in water consumption was noted for mice in the 25 and 
50 ppm groups, the hydration status of exposed mice should be examined as this may 
potentially affect parameters related to glucose metabolism.  Analysis of electrolytes, serum 
aldosterone levels, or hematocrit analysis would provide adequate insight into the hydration 
status of iAs-exposed mice.  In an alternative approach, mice in the experimental and control 
groups could be gavaged to insure that the water consumed by control mice matches that of 
iAs-exposed mice.  Based on the current literature we believe that iAs-exposed mice did not 
suffer from overt dehydration and that the observed impairment of glucose tolerance was 
directly related to specific effects of iAs and its metabolites on physiological processes 
regulating whole-body glucose homeostasis. 
 The results presented in this dissertation have contributed to the establishment of a 
collaborative project between our lab and the research group of Dr. Luz-María Del Razo 
(Cinvestav, Mexico), to investigate the occurrence of diabetes in human populations exposed 
to iAs in drinking-water.  These studies will investigate the relationship between 
interindividual differences in arsenic metabolism and the occurrence and severity of glucose 
intolerance among exposed human subjects.  In addition, plans are underway to investigate 
the potentially synergistic interaction between obesity and iAs-exposure in mice with the aim 
of further defining the diabetogenic effects of arsenic.   
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 In conclusion, the goal of all scientists is to satisfy their curiosity and ultimately 
contribute something of significance to the scientific community.  It is my sincere hope that 
this dissertation represents just the beginning of my efforts towards these goals.   
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